{"gene":"HLA-E","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1998,"finding":"HLA-E binds to and is the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A, as well as CD94/NKG2B and CD94/NKG2C. HLA-E tetramers (recombinant HLA-E/β2m refolded with MHC leader-sequence peptide) bound specifically to CD94/NKG2A, NKG2B, and NKG2C on transfectants but not to KIR family receptors. Surface expression of HLA-E was sufficient to protect target cells from lysis by CD94/NKG2A+ NK cell clones.","method":"HLA-E tetramer binding assay, NK cell cytotoxicity assay, transfection of receptor-expressing cell lines","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional assays with tetramers and cytotoxicity, independently replicated in the same year by Lee et al. (PMID:9560253)","pmids":["9486650"],"is_preprint":false},{"year":1998,"finding":"HLA-E is a major ligand for the NK cell inhibitory receptor CD94/NKG2A. Surface stabilization of HLA-E on .221 transfectants with appropriate HLA class I leader sequence peptides was sufficient to confer protection from CD94/NKG2A+ NK-mediated lysis. Neither the Ig-SF KIR receptors nor ILT2/LIR1 mediated this inhibitory effect. Anti-HLA-E, anti-CD94, or anti-CD94/NKG2A antibodies specifically restored NK lysis, confirming the HLA-E:CD94/NKG2A axis.","method":"NK cell cytotoxicity assay, antibody blocking, transfection of HLA class I allotypes into .221 cells, cold-loading of peptides","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (antibody blocking, peptide loading, NK cytotoxicity), replicates PMID:9486650","pmids":["9560253"],"is_preprint":false},{"year":1998,"finding":"The peptide-binding groove of HLA-E is highly adapted for specific binding of conserved leader sequence peptides from HLA class Ia molecules and is structurally similar to class Ia MHC molecules but with higher specificity along the entire peptide length, unlike the promiscuous grooves of class Ia molecules.","method":"Structural analysis / crystallography (framework review)","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural description reported in a review citing crystallographic data; single source in this corpus for this structural claim","pmids":["9700506"],"is_preprint":false},{"year":1988,"finding":"HLA-E (originally designated HLA-6.2) encodes a protein that associates with β2-microglobulin, establishing it as an expressible MHC class I molecule. It maps between HLA-C and HLA-A on chromosome 6.","method":"Gene transfer into class I-null human lymphoblastoid cell line, immunoprecipitation to detect β2m association, deletion mutant mapping","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct gene transfer with protein detection, foundational identification paper","pmids":["3260916"],"is_preprint":false},{"year":2002,"finding":"The two HLA-E alleles (HLA-E*0101 with Arg107 and HLA-E*0103 with Gly107) differ in peptide affinity, thermal stability, and cell surface expression levels. Crystal structures of HLA-E(G) complexed with two distinct peptides showed no significant conformational differences in the heavy chain between alleles or peptides, but differences in thermal stability and peptide affinity correlated with differential cell surface levels.","method":"Crystal structure determination, thermal stability assay, peptide affinity measurements, cell surface expression quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures plus multiple orthogonal biochemical assays (affinity, stability, surface expression) in one study","pmids":["12411439"],"is_preprint":false},{"year":1999,"finding":"Cell surface expression of HLA-E in mouse cells strictly requires coexpression of human β2-microglobulin. Soluble empty HLA-E/hβ2m complexes display low thermostability, indicating low-affinity β2m interaction contributes to inefficient peptide loading in the ER. The allelic substitution at position 107 (Gly or Arg) greatly affects intracellular transport and cell surface expression.","method":"Transfection of HLA-E ± human β2m into mouse myeloma cells, thermal stability assay, FACS quantification of surface expression","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (transfection, stability, flow cytometry) establishing β2m dependency and allelic effects","pmids":["10064069"],"is_preprint":false},{"year":2000,"finding":"Surface expression of HLA-E requires a functioning TAP molecule to transport HLA class I leader peptides into the ER. Without this peptide supply, HLA-E is unstable and degraded before reaching the cell surface. This mechanism allows NK cells to detect downregulation of classical HLA class I molecules in virally infected or tumor cells.","method":"Crystallographic studies and functional analyses described in review (citing original experimental work on TAP dependency)","journal":"Clinical science","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structural and functional data cited from prior experimental work; review synthesis but based on original crystallographic and cell biology experiments","pmids":["10887053"],"is_preprint":false},{"year":2000,"finding":"HLA-E is expressed on trophoblast cell surfaces and is recognized by the vast majority of decidual NK cells via CD94/NKG2 receptors. HLA-E tetramer binding to decidual NK cells is inhibited by anti-CD94 antibody. The functional consequence of this interaction is inhibition of decidual NK cell cytotoxicity.","method":"HLA-E tetramer staining of decidual NK cells, anti-CD94 antibody blocking, cytotoxicity assays with polyclonal decidual NK cells, immunostaining of trophoblast","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — tetramer staining, antibody blocking, and functional cytotoxicity assays in primary cells","pmids":["10898498"],"is_preprint":false},{"year":2000,"finding":"HLA-E transcription is induced by IFN-γ through an upstream STAT1 binding site and is inducible by CIITA through the SXY regulatory module. HLA-E is not inducible by NF-κB or IRF1 due to divergence in its promoter regulatory elements.","method":"Promoter analysis, transcriptional reporter assays, cis-acting element mapping","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter functional analysis with defined binding sites, single lab","pmids":["11137213"],"is_preprint":false},{"year":2002,"finding":"HLA-E can be recognized by the αβ T cell receptor (TCR) on CD8+ T cells independently of CD94/NKG2C. An αβ CD8+CD94/NKG2C+ CTL clone recognized RMA-S/HLA-E cells loaded with specific HLA class I leader sequence peptides and also a peptide derived from EBV BZLF-1 protein. Anti-clonotypic TCR antibody blocked lysis while anti-CD94 did not, and HLA-E tetramers stained K14 cells in a TCR-dependent manner.","method":"CTL cytotoxicity assay, antibody blocking with anti-TCR and anti-CD94, HLA-E tetramer staining","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (cytotoxicity, antibody blocking, tetramer staining) establishing TCR-dependent HLA-E recognition","pmids":["11920559"],"is_preprint":false},{"year":2003,"finding":"HLA-E cell surface expression in tumor cell lines is related to the availability of free β2-microglobulin in the cytoplasm. Tumor cells with downregulation of HLA class Ia heavy chains (leading to excess β2m) show increased HLA-E surface expression. Addition of human β2m to tumor cells expressing HLA-E(G) allele increased HLA-E surface expression. Total loss of HLA class Ia expression (including β2m mutations) abolished HLA-E surface expression.","method":"Monoclonal antibody staining (3D12) of tumor cell lines, exogenous β2m addition experiments, analysis of cell lines with defined HLA alterations","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab with multiple cell line contexts and β2m supplementation experiments","pmids":["12618909"],"is_preprint":false},{"year":2005,"finding":"Inhibitory NKG2A/CD94 and activating NKG2E/CD94 receptors bind HLA-E with indistinguishable affinities, both higher than the activating NKG2C/CD94 receptor. The peptide presented by HLA-E significantly influences binding affinity of all three receptors, while HLA-E allelic differences (position 107) had no effect on receptor binding affinity.","method":"Quantitative binding affinity measurements and thermodynamic analysis (surface plasmon resonance or equivalent) for three NKG2x/CD94 receptors with HLA-E/peptide complexes","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biophysical affinity measurements with multiple receptor-ligand combinations, peptide variation systematically tested","pmids":["15728498"],"is_preprint":false},{"year":2005,"finding":"Stable surface expression of HLA-E on porcine cells requires appropriate peptide loading (HLA class I leader sequence peptides). HLA-E expression on porcine cells protected them from lysis by human NKG2A+ NK clones. An HLA-E single-chain trimer (SCT) fusing β2m, peptide, and HLA-E heavy chain was engineered and demonstrated correct folding and function, inhibiting NK cytotoxicity and IFN-γ secretion.","method":"Transfection of porcine cell lines, FACS for surface expression, NK cytotoxicity assay, IFN-γ measurement, engineering of single-chain trimer construct","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional cytotoxicity assays in transfected porcine cells, SCT reconstitution validates peptide-dependent HLA-E function","pmids":["15829309"],"is_preprint":false},{"year":2007,"finding":"TNFα, IL-1β, and IFN-γ upregulate cell-surface HLA-E expression on endothelial cells and induce release of soluble HLA-E (sHLA-E). HLA-E upregulation protects IFN-γ-activated endothelial cells from NK-mediated lysis, while sHLA-E protects bystander cells. HLA-E protein expression in normal human non-lymphoid organs is mainly restricted to endothelial cells.","method":"In vitro cytokine stimulation of endothelial cells, flow cytometry for surface HLA-E, NK cell cytotoxicity assay, ELISA for sHLA-E","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cytokine stimulation conditions, cytotoxicity functional readout, sHLA-E quantification; two orthogonal functional outcomes","pmids":["17179229"],"is_preprint":false},{"year":2008,"finding":"Crystal structures of HLA-E complexed with two leader peptides (HLA-Cw*07: VMAPRALLL and HLA-G*01: VMAPRTLFL, both at 2.5 Å resolution) showed that allotypic variations in leader sequences do not cause conformational changes in the HLA-E heavy chain, but subtle changes in peptide conformation within the binding groove profoundly affect recognition by CD94-NKG2 receptors. HLA-Cw*07 peptide (poorly recognized) versus HLA-G*01 peptide (high-affinity ligand) differ in conformation within the groove.","method":"X-ray crystallography at 2.5 Å resolution, structural comparison of peptide-HLA-E complexes","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — two crystal structures determined and compared, mechanistic conclusion about peptide conformation and receptor recognition","pmids":["18339401"],"is_preprint":false},{"year":2011,"finding":"HLA-E expressed on gynecological tumors inhibits CD8+ T cell (CTL) function via CD94/NKG2A receptor interaction. Up to 50% of intraepithelial CTLs expressed the inhibitory CD94/NKG2A receptor. In ovarian cancer, high HLA-E expression completely neutralized the beneficial effect of high CTL infiltration on overall survival, indicating functional inhibition of CTLs by HLA-E:NKG2A interaction in the tumor microenvironment.","method":"Immunohistochemistry on 420 tumor sections, in situ detection of NKG2A+ CTLs, survival analysis linked to HLA-E expression and CTL infiltration","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — large tumor cohort with in situ co-localization; functional inhibition inferred from survival data rather than direct in vitro blocking","pmids":["21670276"],"is_preprint":false},{"year":2014,"finding":"HCMV-driven expansion of NKG2C+ NK cells requires CD94/NKG2C:HLA-E axis and IL-12 from CD14+ monocytes. Blockade of CD94/NKG2C on NK cells or silencing of HLA-E in HCMV-infected fibroblasts greatly impaired expansion of NKG2C+ NK cells. IL-12 neutralization substantially reduced CD25 upregulation and NKG2C+ subset expansion.","method":"NK-monocyte coculture system, NKG2C blockade antibodies, HLA-E siRNA knockdown in infected fibroblasts, IL-12 neutralization","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal knockdown and blocking experiments in a mechanistically defined coculture system","pmids":["25384219"],"is_preprint":false},{"year":2015,"finding":"HLA-E:NKG2A interaction inhibited degranulation of NKG2A+ NK cell subsets with almost all tested peptides. In contrast, NKG2A-NKG2C+ NK cell responses were enhanced only by a restricted set of peptides, most strongly by the HLA-G leader peptide. The HLA-E:G-peptide complex triggered NKG2C receptor internalization (reduced by bafilomycin, indicating lysosomal pathway involvement).","method":"NK cell degranulation assay (CD107a expression), peptide-induced HLA-E surface expression on PBMCs, NKG2C receptor internalization assay with bafilomycin","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional degranulation assays with peptide panel and mechanistic follow-up on receptor internalization; single lab","pmids":["26382247"],"is_preprint":false},{"year":2015,"finding":"During monocyte-to-macrophage differentiation, newly synthesized HLA-E molecules are primarily trafficked to intracellular autophagy-lysosomal vesicles (colocalizing with LC3 and LAMP1) rather than the cell surface, unlike classical HLA class I. Only a small fraction of HLA-E reaches the cell surface, and NK lysis is still inhibited by anti-NKG2A antibody comparably in differentiated and undifferentiated cells.","method":"Confocal microscopy with LC3 and LAMP1 co-localization, subcellular fractionation, flow cytometry, NK cytotoxicity assay in monocytic cell lines and primary monocytes","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct imaging colocalization with functional markers, multiple cell contexts; single lab","pmids":["26310830"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of HLA-E bound to HIV- and Mtb-derived pathogen peptides reveal that despite preferences for canonical primary anchor residues, HLA-E-bound pathogen peptides can adopt alternative conformations within the peptide-binding groove. Combined structural and mutagenesis analyses show greater tolerance for hydrophobic and polar residues in the primary pockets than previously appreciated.","method":"X-ray crystallography of HLA-E/peptide complexes, mutagenesis of binding pockets, biochemical peptide binding studies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures plus mutagenesis and biochemical binding data in one study","pmids":["30087334"],"is_preprint":false},{"year":2018,"finding":"Adaptive NK cells recognize differences between HLA-E-peptide complexes with exquisite specificity via the activating CD94/NKG2C receptor. Prolonged exposure to HLA-E presenting the HLA-G leader peptide VMAPRTLFL enriched adaptive NK cells with low FcεRγ expression, upregulated CD25, increased proliferation, and elevated antibody-dependent cellular cytotoxicity and IFN-γ responses compared to other HLA-E peptide complexes.","method":"NK cell coculture with defined HLA-E peptide complexes, flow cytometry for phenotype markers, functional assays for ADCC and IFN-γ, CD25/FcεRγ expression analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic peptide panel comparison with multiple functional readouts; direct functional consequence of specific HLA-E:peptide complex established","pmids":["30134159"],"is_preprint":false},{"year":2017,"finding":"HLA-E presents glycopeptides from the Mycobacterium tuberculosis protein MPT32 to CD8+ T cells. Recognition by an HLA-E-restricted CD8+ T cell clone required N-terminal O-linked mannosylation of MPT32 by a mannosyltransferase encoded by Rv1002c, establishing the first post-translationally modified Mtb antigen presented by HLA-E.","method":"T cell clone cytotoxicity/recognition assay, HLA-E tetramer staining, Rv1002c mannosyltransferase mutant bacteria, glycopeptide synthesis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — T cell clone recognition with mannosyltransferase mutant establishing PTM requirement; single lab","pmids":["28676677"],"is_preprint":false},{"year":2019,"finding":"Senescent dermal fibroblasts upregulate HLA-E expression, and this HLA-E interacts with the inhibitory receptor NKG2A on NK cells and highly differentiated CD8+ T cells to inhibit immune responses against senescent cells. HLA-E induction in senescent cells is driven by SASP-related pro-inflammatory cytokines and regulated by p38 MAP kinase signaling in vitro. Blocking HLA-E:NKG2A interaction boosted immune responses against senescent cells in vitro.","method":"Senescence induction in primary fibroblasts, flow cytometry for HLA-E expression, NK/CD8 T cell killing assay, p38 inhibitor treatment, NKG2A blocking antibody","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (p38 inhibitor, cytokines, NKG2A blockade) with defined functional readout of immune killing","pmids":["31160572"],"is_preprint":false},{"year":2019,"finding":"HIV-1 Nef protein downmodulates HLA-E surface levels on infected primary CD4+ T cells by targeting the cytoplasmic tail of HLA-E. Tail-swap experiments exchanging the cytoplasmic tail of HLA-A2 with that of HLA-E demonstrated Nef specifically targets the HLA-E cytoplasmic tail. HIV-1 mutants lacking functional Nef (and to a lesser extent Vpu) showed impaired HLA-E downmodulation.","method":"Primary HIV-1 strain infection of CD4+ T cells, single Nef/Vpu expression in T cell lines, cytoplasmic tail swap constructs (HLA-A2/HLA-E chimeras), flow cytometry","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — tail swap mutagenesis plus multiple viral mutant analyses establishing Nef as the effector targeting the HLA-E cytoplasmic tail","pmids":["31375574"],"is_preprint":false},{"year":2020,"finding":"SARS-CoV-2 spike 1 protein (SP1) expressed intracellularly in lung epithelial cells induces HLA-E surface expression via presentation of an SP1-derived HLA-E-binding peptide, leading to increased NKG2A/CD94 expression on NK cells and reduced NK cell degranulation via HLA-E/NKG2A interaction. The GATA3 transcription factor was ruled out as responsible for HLA-E upregulation.","method":"Transfection of lung epithelial cells with SARS-CoV-2 spike constructs, flow cytometry for HLA-E and NK cell activation markers, NK cell co-culture assay, immunofluorescence, GATA3 inhibitor experiments","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cell transfection with functional NK readout; single lab; peptide identification supporting HLA-E upregulation mechanism","pmids":["32859121"],"is_preprint":false},{"year":2021,"finding":"HLA-E-restricted HIV-1-specific CD8+ T cell clones and allogeneic CD8+ T cells transduced with their TCRs suppressed HIV-1 replication in CD4+ T cells in vitro. HLA-E-restricted T cells were primed in vitro and recognized Gag-derived peptides presented by HLA-E.","method":"In vitro T cell priming, TCR transduction into allogeneic CD8+ T cells, HIV-1 replication suppression assay in CD4+ T cells","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — TCR transduction establishing antigen specificity, functional suppression of viral replication as direct readout","pmids":["33766848"],"is_preprint":false},{"year":2022,"finding":"The SARS-CoV-2 Non-structural protein 13 (Nsp13) encodes a peptide presented by HLA-E that prevents binding of HLA-E to the inhibitory receptor NKG2A (unlike self-peptides), rendering target cells susceptible to NKG2A-expressing NK cell attack. NKG2A+ NK cells were specifically activated and proficiently limited SARS-CoV-2 replication in infected lung epithelial cells in vitro.","method":"Peptide-HLA-E binding assay, NKG2A blocking experiments, NK cell activation assay, viral replication suppression assay in lung epithelial cells, patient NK cell phenotyping","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal assays (peptide binding, NKG2A blocking, NK activation, viral replication) establishing viral peptide-HLA-E-NKG2A mechanism","pmids":["35235832"],"is_preprint":false},{"year":2022,"finding":"Crystal structures of HLA-E bound to VL9 (MHC class Ia signal peptides) versus pathogen-derived peptides reveal that VL9 positions close to the α2 helix via three HLA-E-exclusive amino acids. Non-VL9 pathogen peptides introduce an alternative peptide-binding motif and re-configure a key TCR-interacting α2 region, providing the structural basis for VL9- versus non-VL9-HLA-E immune discrimination. Small-angle X-ray scattering revealed that non-VL9 HLA-E complexes are conformationally dynamic in solution compared to VL9 complexes.","method":"X-ray crystallography of multiple HLA-E/peptide complexes, small-angle X-ray scattering (SAXS), mutagenesis of key residues, peptide excess experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures plus SAXS solution data, mutagenesis, establishing distinct structural bases for VL9 vs. non-VL9 binding","pmids":["35705051"],"is_preprint":false},{"year":2023,"finding":"Among 16 common classical HLA class I signal peptide variants, only 6 can be efficiently processed to generate epitopes enabling CD94/NKG2 engagement ('functional SPs'). The single functional HLA-B SP (HLA-B/-21M) induces high HLA-E expression but provides the lowest NKG2 receptor recognition, and competes with other SPs for providing epitope to HLA-E, thereby reducing overall CD94/NKG2A recognition of target cells.","method":"Systematic quantitative analysis of 16 SP variants for HLA-E stabilization and CD94/NKG2A/C binding, competitive peptide loading assays, NK cell functional assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic quantitative screen of all major SP variants with functional NK assays and competition experiments; multiple orthogonal approaches","pmids":["37264229"],"is_preprint":false},{"year":2023,"finding":"HLA-E is largely retained in the endoplasmic reticulum after synthesis due to limited supply of high-affinity peptides, with further fine-tuning by its cytoplasmic tail. Once at the cell surface, HLA-E is unstable and rapidly internalized; its cytoplasmic tail is required for HLA-E internalization, resulting in enrichment in late and recycling endosomes. This distinguishes HLA-E trafficking from classical HLA class I.","method":"Live cell imaging, FRAP, subcellular fractionation, cytoplasmic tail deletion/mutation constructs, trafficking inhibitor studies, comparison with classical HLA class I","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live imaging and tail mutagenesis with multiple orthogonal methods defining HLA-E intracellular transport pathway","pmids":["37140910"],"is_preprint":false},{"year":2023,"finding":"HLA-E presents EBV LMP-1-derived peptides (GGDPHLPTL or GGDPPLPTL) to NKG2A+ NK and CD8+ T cells in an inhibitory manner. EBV strains encoding both peptide variants were associated with symptomatic EBV reactivations. The highly expressed HLA-E*0103/0103 genotype is protective against infectious mononucleosis through induction of BZLF1-specific HLA-E-restricted CD8+ T cell responses that efficiently prevent viral dissemination in vitro.","method":"Functional NK and CD8+ T cell assays, viral dissemination assay in vitro, large cohort study (1404 patients), peptide-HLA-E binding experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional in vitro viral suppression assays combined with large clinical cohort; mechanistic NKG2A/LMP-1/HLA-E axis defined","pmids":["36477802"],"is_preprint":false},{"year":2023,"finding":"Platelet-derived RGS18 promotes HLA-E expression on circulating tumor cells (CTCs) through the AKT-GSK3β-CREB signaling pathway, enabling CTCs to evade NK cell-mediated immune surveillance via the HLA-E:CD94-NKG2A immune checkpoint. Disruption of this interaction by NKG2A blockade or HLA-E knockdown enhanced NK-mediated killing in vitro and prevented tumor metastasis in vivo.","method":"Single-cell transcriptomics, in vitro NK killing assay, in vivo tumor metastasis mouse model, HLA-E knockdown, NKG2A blockade, RGS18 overexpression/knockdown with AKT/GSK3β/CREB pathway analysis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vitro and in vivo experiments establishing RGS18-AKT-GSK3β-CREB-HLA-E pathway with functional NK and metastasis readouts","pmids":["36706761"],"is_preprint":false},{"year":2023,"finding":"Antigen-specific human NK cell memory against HIV and influenza is mediated largely through the activating CD94/NKG2C receptor recognizing HLA-E in an epitope-specific manner. Single-cell cloning validated permanent antigen specificity of individual memory NK cells. KLRG1, α4β7, and NKG2C were identified as biomarkers of antigen-specific NK memory, and individual HLA-E-restricted peptides from HIV-1 and influenza constitute dominant NK cell responses in infected persons.","method":"Single-cell cloning of NK cells, HLA-E tetramer staining, NKG2C blocking, peptide-HLA-E binding assays, immunophenotyping of infected patient NK cells","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-cell cloning establishing antigen specificity, NKG2C blocking, HLA-E tetramers; multiple orthogonal methods","pmids":["38064568"],"is_preprint":false},{"year":2023,"finding":"High-throughput yeast-display screening identified 500 unique peptides that bind both HLA-E and CD94/NKG2A or CD94/NKG2C, including CMV proteome-derived peptides. Peptides selectively activating NKG2C+ NK cells were identified. Prediction algorithms trained on yeast-display selections identified human and CMV proteome-derived HLA-E-presented peptides capable of signaling through both inhibitory and activating receptors.","method":"Yeast-displayed peptide library screen, HLA-E/CD94/NKG2x binding selection, NK cell functional assays, machine learning-based prediction algorithm","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — large-scale functional screen with direct NK cell activation readouts, multiple validation experiments","pmids":["37558657"],"is_preprint":false},{"year":2021,"finding":"HLA-E-restricted CD8+ T cells from CMV-infected individuals express inhibitory KIR2DL1 and KIR2DL2/L3 when bearing high-affinity TCRs for HLA-E/self-peptide, while T cells with lower-affinity TCRs expressed the activating receptor NKG2C. Activation of high-affinity TCR-bearing T cells was regulated by KIR2D receptor interaction with HLA-C, providing a mechanism for self/non-self discrimination by HLA-E-restricted T cells.","method":"RNA sequencing, flow cytometry, TCR affinity measurement, KIR2D blocking experiments, CMV UL40/HLA-E tetramer staining","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — TCR affinity correlation with NKR expression, KIR blocking establishing functional regulation; multiple orthogonal approaches","pmids":["33893172"],"is_preprint":false},{"year":2023,"finding":"HLA-E-restricted SARS-CoV-2-specific CD8+ T cell clones with diverse TCRs recognized five SARS-CoV-2-derived peptides presented by HLA-E and suppressed viral replication in Calu-3 lung epithelial cells. SARS-CoV-2 infection markedly downregulated classical HLA class I (HLA-A, B, C) expression while HLA-E expression was not affected, enabling continued HLA-E-restricted T cell recognition.","method":"T cell clone isolation and characterization, HLA-E peptide-specific suppression of SARS-CoV-2 replication, flow cytometry for HLA class I and HLA-E surface expression in infected cells, primary reconstituted human airway epithelial cells","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — T cell clone functional suppression assay, infection-induced HLA class I modulation measured in primary and cell line models","pmids":["37390223"],"is_preprint":false}],"current_model":"HLA-E is a minimally polymorphic, non-classical MHC class I molecule that assembles as a β2-microglobulin-associated trimer requiring high-affinity peptides (predominantly nonameric leader-sequence peptides, VL9, derived from classical HLA-A/B/C/G signal sequences) for stable cell-surface expression; at the surface it primarily engages CD94/NKG2A (inhibitory) and CD94/NKG2C (activating) receptors on NK cells and T cell subsets to regulate cytotoxicity, with the peptide identity and conformation within the HLA-E groove critically determining receptor binding affinity and functional outcome; HLA-E is largely ER-retained due to limited high-affinity peptide availability, its cytoplasmic tail facilitates rapid surface internalization into late/recycling endosomes, its expression is transcriptionally induced by IFN-γ (via STAT1) and CIITA but not NF-κB or IRF1, and it can also present lower-affinity pathogen-derived peptides to αβ TCR-bearing CD8+ T cells, enabling both innate immune surveillance and adaptive anti-pathogen responses."},"narrative":{"mechanistic_narrative":"HLA-E is a non-classical MHC class I molecule that functions as a central sensor of cellular integrity, assembling as a β2-microglobulin-associated complex that requires high-affinity peptide loading—predominantly nonameric leader-sequence (VL9) peptides derived from classical HLA class Ia and HLA-G signal sequences—for stable cell-surface expression [PMID:3260916, PMID:9700506, PMID:37264229]. Surface stabilization is strictly dependent on β2-microglobulin availability, TAP-mediated transport of leader peptides into the ER, and the allelic identity at position 107 governing thermal stability and surface levels [PMID:10064069, PMID:10887053, PMID:12411439, PMID:12618909]. At the cell surface, HLA-E primarily engages the CD94/NKG2 receptor family on NK cells and T cell subsets: it is the dominant ligand for the inhibitory CD94/NKG2A receptor, whose engagement protects target cells from NK-mediated lysis, and for the activating CD94/NKG2C receptor, with the receptor-bound outcome dictated by the precise conformation of the peptide within the binding groove rather than by heavy-chain allelic differences [PMID:9486650, PMID:9560253, PMID:15728498, PMID:18339401]. Because peptide supply links HLA-E surface display to the status of classical class I expression, this axis allows NK cells to detect downregulation of HLA class Ia in infected or transformed cells [PMID:10887053, PMID:12618909]. HLA-E additionally presents lower-affinity pathogen-derived peptides—from HCMV, EBV, HIV, Mycobacterium tuberculosis, and SARS-CoV-2—to αβ TCR-bearing CD8+ T cells and to adaptive/memory NK cells, with non-VL9 peptides adopting alternative groove conformations that reconfigure the receptor- and TCR-interacting α2 region [PMID:11920559, PMID:35705051, PMID:28676677, PMID:33766848, PMID:35235832, PMID:38064568, PMID:37390223]. HLA-E trafficking is distinct from classical class I: limited high-affinity peptide causes ER retention, and its cytoplasmic tail drives rapid surface internalization into late and recycling endosomes, a feature exploited by HIV-1 Nef to downmodulate surface HLA-E [PMID:37140910, PMID:31375574, PMID:26310830]. Its expression is transcriptionally induced by IFN-γ via STAT1 and by CIITA, but not by NF-κB or IRF1, and is upregulated on endothelial cells, senescent cells, and tumor cells where the HLA-E:NKG2A interaction acts as an immune checkpoint suppressing NK and CTL responses [PMID:11137213, PMID:17179229, PMID:31160572, PMID:21670276, PMID:36706761].","teleology":[{"year":1988,"claim":"Established that the HLA-E locus encodes a genuinely expressible MHC class I protein rather than a pseudogene, fixing it as a candidate immune molecule.","evidence":"gene transfer into class I-null lymphoblastoid cells with immunoprecipitation detecting β2m association, and deletion mapping on chromosome 6","pmids":["3260916"],"confidence":"High","gaps":["Did not define what peptides HLA-E presents","No receptor or functional role identified","Tissue distribution and induction unknown"]},{"year":1998,"claim":"Defined the core function of HLA-E by showing it is the predominant ligand for CD94/NKG2 receptors and that its surface display inhibits NK cytotoxicity, explaining how missing-self surveillance is licensed.","evidence":"HLA-E tetramer binding to NKG2A/B/C transfectants, peptide-loaded .221 transfectants, antibody blocking, and NK cytotoxicity assays","pmids":["9486650","9560253"],"confidence":"High","gaps":["Did not quantify differential affinities of activating vs inhibitory receptors","Structural basis of peptide-dependent recognition unresolved","Did not address TCR-mediated recognition"]},{"year":1998,"claim":"Showed the HLA-E groove is uniquely specialized for conserved leader-sequence peptides with high specificity along the entire peptide, distinguishing it from promiscuous class Ia molecules.","evidence":"structural analysis citing crystallographic data (review framework)","pmids":["9700506"],"confidence":"Medium","gaps":["Single review-derived structural claim in this corpus","Did not establish which peptide features control receptor recognition"]},{"year":2000,"claim":"Linked HLA-E surface expression to the TAP peptide-supply pathway, establishing the mechanistic logic by which NK cells sense loss of classical class I presentation.","evidence":"review synthesis of crystallographic and cell-biology experiments on TAP dependency","pmids":["10887053"],"confidence":"Medium","gaps":["Review synthesis rather than primary data in this entry","Quantitative peptide affinity thresholds not defined"]},{"year":1999,"claim":"Demonstrated that β2-microglobulin availability and the position-107 allelic substitution govern HLA-E assembly, transport, and surface levels, identifying biochemical bottlenecks in its display.","evidence":"transfection of HLA-E ± human β2m into mouse myeloma cells with thermal stability assays and FACS quantification","pmids":["10064069"],"confidence":"High","gaps":["Did not connect surface levels to receptor recognition outcomes","In vivo relevance of allelic effect untested here"]},{"year":2000,"claim":"Extended HLA-E function to a physiological context by showing trophoblast HLA-E inhibits decidual NK cytotoxicity via CD94/NKG2, implicating it in maternal-fetal tolerance.","evidence":"HLA-E tetramer staining of decidual NK cells, anti-CD94 blocking, and primary-cell cytotoxicity assays","pmids":["10898498"],"confidence":"High","gaps":["Did not identify the in vivo peptide presented by trophoblast HLA-E","Did not address activating receptor outcomes"]},{"year":2000,"claim":"Identified the transcriptional control of HLA-E, showing IFN-γ/STAT1 and CIITA induction but insensitivity to NF-κB and IRF1, distinguishing its regulation from inflammatory induction.","evidence":"promoter reporter assays and cis-element mapping","pmids":["11137213"],"confidence":"Medium","gaps":["Single-lab promoter analysis","Did not characterize regulation in primary tissue contexts"]},{"year":2002,"claim":"Showed that HLA-E allelic variants differ in peptide affinity and stability but adopt indistinguishable heavy-chain conformations, separating expression-level effects from structural effects.","evidence":"crystal structures of HLA-E(G) with two peptides plus thermal stability, affinity, and surface expression measurements","pmids":["12411439"],"confidence":"High","gaps":["Did not test receptor-binding consequences of allelic differences directly","Peptide repertoire breadth not assessed"]},{"year":2002,"claim":"Established a second recognition arm by showing HLA-E can be recognized directly by αβ TCRs on CD8+ T cells independently of CD94/NKG2C, including a viral (EBV BZLF-1) peptide.","evidence":"CTL cytotoxicity with anti-TCR vs anti-CD94 blocking and TCR-dependent HLA-E tetramer staining","pmids":["11920559"],"confidence":"High","gaps":["TCR diversity and peptide breadth not defined","In vivo protective role untested"]},{"year":2003,"claim":"Connected HLA-E surface levels to free cytoplasmic β2m in tumor cells, showing class Ia downregulation can paradoxically raise HLA-E and shape NK evasion.","evidence":"antibody staining of tumor lines with defined HLA alterations and exogenous β2m supplementation","pmids":["12618909"],"confidence":"Medium","gaps":["Single-lab correlative cell-line study","Functional NK outcome of increased HLA-E not directly tested here"]},{"year":2005,"claim":"Quantified the biophysical hierarchy of CD94/NKG2 receptor binding and demonstrated peptide identity—not allelic variation—controls receptor affinity, defining the molecular tuning of HLA-E signalling.","evidence":"quantitative affinity and thermodynamic measurements for NKG2A/C/E with HLA-E/peptide complexes","pmids":["15728498"],"confidence":"High","gaps":["Did not resolve how peptide alters the recognition interface structurally","Functional NK consequences inferred not directly measured here"]},{"year":2005,"claim":"Validated peptide-dependent HLA-E function in a xenogeneic context and engineered a single-chain trimer, providing a reagent and proof that loaded HLA-E suffices to inhibit NK responses.","evidence":"porcine cell transfection, NK cytotoxicity and IFN-γ assays, and single-chain β2m-peptide-HLA-E construct","pmids":["15829309"],"confidence":"High","gaps":["SCT may not capture native conformational dynamics","Restricted to inhibitory receptor readouts"]},{"year":2007,"claim":"Demonstrated cytokine-driven HLA-E upregulation on endothelium and release of soluble HLA-E, extending its immunomodulatory reach to bystander protection.","evidence":"cytokine stimulation of endothelial cells, flow cytometry, NK cytotoxicity, and sHLA-E ELISA","pmids":["17179229"],"confidence":"High","gaps":["Mechanism of sHLA-E generation not defined","In vivo significance of soluble form untested"]},{"year":2008,"claim":"Provided the structural basis for differential receptor recognition by showing subtle peptide conformational changes in the groove—not heavy-chain changes—dictate CD94/NKG2 binding.","evidence":"X-ray crystallography of HLA-E with HLA-Cw*07 and HLA-G*01 leader peptides at 2.5 Å","pmids":["18339401"],"confidence":"High","gaps":["Limited to two leader peptides","Did not address pathogen-peptide conformations"]},{"year":2011,"claim":"Showed HLA-E:NKG2A acts as a functional checkpoint in tumors, neutralizing the survival benefit of CTL infiltration and implicating it in cancer immune evasion.","evidence":"immunohistochemistry on 420 tumor sections with in situ NKG2A+ CTL detection and survival analysis","pmids":["21670276"],"confidence":"Medium","gaps":["Functional inhibition inferred from survival rather than direct in vitro blocking","Peptides presented in tumor context not identified"]},{"year":2014,"claim":"Defined the HLA-E:NKG2C axis as a driver of HCMV-induced adaptive NK cell expansion requiring monocyte-derived IL-12, linking HLA-E to NK memory formation.","evidence":"NK-monocyte coculture, NKG2C blockade, HLA-E siRNA in infected fibroblasts, and IL-12 neutralization","pmids":["25384219"],"confidence":"High","gaps":["Specific HLA-E peptide driving expansion not pinpointed here","Durability of memory not assessed"]},{"year":2015,"claim":"Distinguished the peptide selectivity of inhibitory versus activating signalling, showing nearly all peptides inhibit via NKG2A while only restricted peptides (notably HLA-G leader) activate NKG2C, with HLA-E:G triggering lysosomal NKG2C internalization.","evidence":"degranulation (CD107a) assays with a peptide panel and bafilomycin-sensitive NKG2C internalization assays","pmids":["26382247"],"confidence":"Medium","gaps":["Single-lab functional dataset","Structural basis of activating peptide selectivity not resolved here"]},{"year":2015,"claim":"Revealed that during macrophage differentiation HLA-E is preferentially routed into autophagy-lysosomal vesicles rather than the surface, indicating cell-state-specific trafficking control.","evidence":"confocal LC3/LAMP1 colocalization, subcellular fractionation, flow cytometry, and NK cytotoxicity in monocytic cells","pmids":["26310830"],"confidence":"Medium","gaps":["Functional purpose of intracellular HLA-E pool unclear","Single-lab study"]},{"year":2017,"claim":"Showed HLA-E can present post-translationally modified (O-mannosylated) mycobacterial glycopeptides to CD8+ T cells, expanding the chemical space of HLA-E antigens.","evidence":"T cell clone recognition assays, HLA-E tetramers, Rv1002c mannosyltransferase mutant bacteria, and synthetic glycopeptides","pmids":["28676677"],"confidence":"Medium","gaps":["Single clone/single-lab evidence","In vivo protective relevance untested"]},{"year":2018,"claim":"Demonstrated structurally that pathogen-derived peptides occupy the HLA-E groove with greater anchor-residue tolerance and alternative conformations than canonical VL9, broadening the predicted HLA-E pathogen peptidome.","evidence":"X-ray crystallography of HLA-E/HIV and Mtb peptide complexes with pocket mutagenesis and binding studies","pmids":["30087334"],"confidence":"High","gaps":["Receptor/TCR consequences of these conformations not directly measured here","Limited peptide set"]},{"year":2018,"claim":"Showed adaptive NK cells discriminate HLA-E peptide complexes with exquisite specificity via NKG2C, with the HLA-G leader peptide selectively enriching functionally superior adaptive NK cells.","evidence":"NK coculture with defined HLA-E peptide complexes, phenotyping, and ADCC/IFN-γ functional assays","pmids":["30134159"],"confidence":"High","gaps":["Molecular basis of peptide-specific NKG2C licensing not resolved here","In vivo selection dynamics untested"]},{"year":2019,"claim":"Identified HLA-E as an immune-evasion signal on senescent cells driven by SASP cytokines and p38 MAPK, inhibiting NK and CD8 clearance via NKG2A.","evidence":"senescence induction in fibroblasts, HLA-E flow cytometry, killing assays, p38 inhibition, and NKG2A blockade","pmids":["31160572"],"confidence":"High","gaps":["Peptide presented by senescent HLA-E not identified","In vivo senescent-cell clearance not tested"]},{"year":2019,"claim":"Mapped HIV-1 Nef-mediated HLA-E downmodulation to the HLA-E cytoplasmic tail, revealing a virus-driven manipulation of HLA-E surface display.","evidence":"primary HIV-1 infection of CD4+ T cells, single Nef/Vpu expression, and HLA-A2/HLA-E tail-swap chimeras with flow cytometry","pmids":["31375574"],"confidence":"High","gaps":["Trafficking machinery engaged by Nef not defined here","Net effect on NK vs T cell recognition in vivo unclear"]},{"year":2020,"claim":"Showed SARS-CoV-2 spike-derived peptide induces HLA-E surface display and suppresses NK degranulation via NKG2A, an early inhibitory immune-evasion mechanism.","evidence":"spike construct transfection of lung epithelial cells, NK coculture, immunofluorescence, and GATA3 inhibition","pmids":["32859121"],"confidence":"Medium","gaps":["Single-lab study","Transcriptional driver of HLA-E upregulation not positively identified"]},{"year":2021,"claim":"Demonstrated HLA-E-restricted, HIV Gag-specific CD8+ T cells can suppress viral replication and that their TCRs are transferable, establishing therapeutic potential for HLA-E-restricted T cells.","evidence":"in vitro T cell priming, TCR transduction into allogeneic CD8+ T cells, and HIV-1 replication suppression assays","pmids":["33766848"],"confidence":"High","gaps":["In vivo efficacy untested","Breadth of protective epitopes limited"]},{"year":2021,"claim":"Revealed a self/non-self discrimination mechanism in which TCR affinity for HLA-E/self-peptide dictates KIR2D versus NKG2C receptor expression on HLA-E-restricted T cells, regulating their activation via HLA-C.","evidence":"RNA-seq, TCR affinity measurement, KIR2D blocking, and CMV UL40/HLA-E tetramer staining","pmids":["33893172"],"confidence":"High","gaps":["Generality across antigens not established","In vivo regulatory consequences untested"]},{"year":2022,"claim":"Provided the structural rationale for VL9 versus non-VL9 discrimination, showing pathogen peptides reconfigure the TCR-interacting α2 region and make non-VL9 HLA-E complexes conformationally dynamic.","evidence":"multiple crystal structures, SAXS solution analysis, and mutagenesis of HLA-E-exclusive residues","pmids":["35705051"],"confidence":"High","gaps":["Functional receptor outcomes of dynamic complexes not directly quantified here","Limited to selected peptides"]},{"year":2022,"claim":"Identified a SARS-CoV-2 Nsp13 peptide that, unlike self-peptides, blocks HLA-E:NKG2A engagement and thereby sensitizes infected cells to NKG2A+ NK attack, defining a peptide-driven activating mechanism.","evidence":"peptide-HLA-E binding, NKG2A blocking, NK activation, and viral replication suppression in lung epithelial cells","pmids":["35235832"],"confidence":"High","gaps":["In vivo relevance during infection not established","Structural basis of disrupted NKG2A binding not resolved here"]},{"year":2023,"claim":"Systematically defined which classical class I signal peptide variants are functionally processed for CD94/NKG2 engagement, showing surface HLA-E level and receptor recognition can be decoupled and that signal peptides compete for HLA-E.","evidence":"quantitative screen of 16 SP variants for HLA-E stabilization and CD94/NKG2A/C binding with competitive loading and NK assays","pmids":["37264229"],"confidence":"High","gaps":["In vivo consequences of SP competition not measured","Did not extend to pathogen peptides"]},{"year":2023,"claim":"Defined the distinctive trafficking itinerary of HLA-E—ER retention from limited peptide and cytoplasmic-tail-driven surface internalization into late/recycling endosomes—setting it apart from classical class I.","evidence":"live imaging, FRAP, fractionation, cytoplasmic tail mutants, and trafficking inhibitor studies","pmids":["37140910"],"confidence":"High","gaps":["Endosomal recycling regulators not identified","Functional consequence of intracellular pool unresolved"]},{"year":2023,"claim":"Established a platelet-RGS18-AKT-GSK3β-CREB pathway driving HLA-E on circulating tumor cells to evade NK surveillance and promote metastasis, identifying a targetable upstream regulator.","evidence":"single-cell transcriptomics, NK killing assays, HLA-E knockdown, NKG2A blockade, and in vivo metastasis models","pmids":["36706761"],"confidence":"High","gaps":["Peptide presented by CTC HLA-E not defined","Generalizability across tumor types untested"]},{"year":2023,"claim":"Established antigen-specific human NK cell memory mediated by NKG2C recognition of HLA-E peptide complexes, with single-cell cloning proving permanent epitope specificity.","evidence":"single-cell NK cloning, HLA-E tetramers, NKG2C blocking, and patient NK phenotyping for HIV and influenza","pmids":["38064568"],"confidence":"High","gaps":["Mechanism of memory imprinting not defined","In vivo protective durability untested"]},{"year":2023,"claim":"Used high-throughput yeast display to map a broad HLA-E peptidome capable of inhibitory and activating receptor signalling and trained predictive algorithms, expanding the known functional peptide space.","evidence":"yeast-display peptide library screen with HLA-E/CD94/NKG2x selection, NK functional assays, and machine-learning prediction","pmids":["37558657"],"confidence":"High","gaps":["In vivo presentation of predicted peptides unverified","Structural rules underlying activating selection not derived"]},{"year":2023,"claim":"Showed HLA-E-restricted CD8+ T cells recognize multiple SARS-CoV-2 peptides and suppress replication, with HLA-E surface levels preserved while classical class I is downregulated during infection—favoring HLA-E-restricted surveillance.","evidence":"T cell clone suppression assays and flow cytometry of HLA class I vs HLA-E in infected airway epithelial cells","pmids":["37390223"],"confidence":"High","gaps":["Mechanism preserving HLA-E during infection not defined","In vivo protection untested"]},{"year":2023,"claim":"Demonstrated EBV LMP-1 peptides presented by HLA-E act through NKG2A to inhibit NK and CD8 responses, while the high-expressing HLA-E*0103 genotype confers protection via BZLF1-specific HLA-E-restricted CD8 T cells.","evidence":"functional NK/CD8 and viral dissemination assays plus a 1404-patient cohort and peptide-HLA-E binding studies","pmids":["36477802"],"confidence":"High","gaps":["Mechanism linking genotype to protective T cell priming not fully resolved","Causality of clinical association limited"]},{"year":null,"claim":"It remains unresolved how the integrated peptide repertoire, allelic dosage, trafficking regulators, and competing signal peptides combine in vivo to set the balance between inhibitory and activating HLA-E signalling for therapeutic targeting.","evidence":"no single study in the corpus reconciles peptidome breadth with in vivo NK/T cell outcomes","pmids":[],"confidence":"Low","gaps":["No in vivo map of which peptides dominate HLA-E presentation in healthy versus diseased tissue","Endosomal recycling regulators of HLA-E unidentified","Predictive rules distinguishing activating from inhibitory peptides not structurally complete"]}],"mechanism_profile":{"molecular_activity":[],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,7,13,29]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5,6,29]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[29,18]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[18]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,7,9,16,30,32]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,5,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,24,26,30,31,35]}],"complexes":["HLA-E/β2-microglobulin/peptide class I complex"],"partners":["B2M","KLRD1","KLRC1","KLRC2","TAP","NEF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P13747","full_name":"HLA class I histocompatibility antigen, alpha chain E","aliases":["MHC class I antigen E"],"length_aa":358,"mass_kda":40.1,"function":"Non-classical major histocompatibility class Ib molecule involved in immune self-nonself discrimination. In complex with B2M/beta-2-microglobulin binds nonamer self-peptides derived from the signal sequence of classical MHC class Ia molecules (VL9 peptides - VMAPRT[V/L][L/V/I/F]L) (PubMed:18083576, PubMed:18339401, PubMed:35705051, PubMed:37264229, PubMed:9754572). Peptide-bound HLA-E-B2M heterotrimeric complex primarily functions as a ligand for natural killer (NK) cell inhibitory receptor KLRD1-KLRC1, enabling NK cells to monitor the expression of other MHC class I molecules in healthy cells and to tolerate self (PubMed:17179229, PubMed:18083576, PubMed:37264229, PubMed:9486650, PubMed:9754572). Upon cellular stress, preferentially binds signal sequence-derived peptides from stress-induced chaperones and is no longer recognized by NK cell inhibitory receptor KLRD1-KLRC1, resulting in impaired protection from NK cells (PubMed:12461076). Binds signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules and acts as a ligand for NK cell activating receptor KLRD1-KLRC2, likely playing a role in the generation and effector functions of adaptive NK cells and in maternal-fetal tolerance during pregnancy (PubMed:30134159, PubMed:37264229, PubMed:9754572). Besides self-peptides, can also bind and present pathogen-derived peptides conformationally similar to VL9 peptides to alpha-beta T cell receptor (TCR) on unconventional CD8-positive cytotoxic T cells, ultimately triggering antimicrobial immune response (PubMed:16474394, PubMed:20195504, PubMed:30087334, PubMed:34228645). Presents HIV gag peptides (immunodominant KAFSPEVIPMF and subdominant KALGPAATL epitopes) predominantly to CD8-positive T cell clones expressing a TRAV17-containing TCR, triggering HLA-E-restricted T cell responses (PubMed:34228645). Presents mycobacterial peptides to HLA-E-restricted CD8-positive T cells eliciting both cytotoxic and immunoregulatory functions (PubMed:20195504, PubMed:35705051) (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells (Microbial infection) May bind HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells (PubMed:32859121). Binds SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening of antiviral immune surveillance (PubMed:32859121)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13747/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HLA-E","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HLA-E","total_profiled":1310},"omim":[{"mim_id":"613609","title":"HOMEOSTATIC IRON REGULATOR; HFE","url":"https://www.omim.org/entry/613609"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"603771","title":"PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 10; PPP1R10","url":"https://www.omim.org/entry/603771"},{"mim_id":"602894","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY D, MEMBER 1; KLRD1","url":"https://www.omim.org/entry/602894"},{"mim_id":"602891","title":"KILLER CELL LECTIN-LIKE RECEPTOR, SUBFAMILY C, MEMBER 2; KLRC2","url":"https://www.omim.org/entry/602891"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HLA-E"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P13747","domains":[{"cath_id":"3.30.500.10","chopping":"22-200","consensus_level":"high","plddt":96.2909,"start":22,"end":200},{"cath_id":"2.60.40.10","chopping":"206-293","consensus_level":"high","plddt":95.4244,"start":206,"end":293}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13747","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13747-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13747-F1-predicted_aligned_error_v6.png","plddt_mean":87.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HLA-E","jax_strain_url":"https://www.jax.org/strain/search?query=HLA-E"},"sequence":{"accession":"P13747","fasta_url":"https://rest.uniprot.org/uniprotkb/P13747.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13747/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13747"}},"corpus_meta":[{"pmid":"9486650","id":"PMC_9486650","title":"HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9486650","citation_count":1823,"is_preprint":false},{"pmid":"9560253","id":"PMC_9560253","title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9560253","citation_count":844,"is_preprint":false},{"pmid":"28504668","id":"PMC_28504668","title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.","date":"2017","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/28504668","citation_count":490,"is_preprint":false},{"pmid":"31160572","id":"PMC_31160572","title":"Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31160572","citation_count":430,"is_preprint":false},{"pmid":"10898498","id":"PMC_10898498","title":"HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10898498","citation_count":290,"is_preprint":false},{"pmid":"36706761","id":"PMC_36706761","title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36706761","citation_count":272,"is_preprint":false},{"pmid":"12411439","id":"PMC_12411439","title":"HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12411439","citation_count":268,"is_preprint":false},{"pmid":"2249951","id":"PMC_2249951","title":"Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue.","date":"1990","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2249951","citation_count":225,"is_preprint":false},{"pmid":"3260916","id":"PMC_3260916","title":"HLA-E. A novel HLA class I gene expressed in resting T lymphocytes.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3260916","citation_count":217,"is_preprint":false},{"pmid":"21670276","id":"PMC_21670276","title":"HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21670276","citation_count":190,"is_preprint":false},{"pmid":"32409305","id":"PMC_32409305","title":"The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32409305","citation_count":187,"is_preprint":false},{"pmid":"15728498","id":"PMC_15728498","title":"Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15728498","citation_count":176,"is_preprint":false},{"pmid":"17179229","id":"PMC_17179229","title":"Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17179229","citation_count":161,"is_preprint":false},{"pmid":"25384219","id":"PMC_25384219","title":"IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25384219","citation_count":159,"is_preprint":false},{"pmid":"9700506","id":"PMC_9700506","title":"Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G.","date":"1998","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9700506","citation_count":142,"is_preprint":false},{"pmid":"12618909","id":"PMC_12618909","title":"Analysis of HLA-E expression in human tumors.","date":"2003","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12618909","citation_count":136,"is_preprint":false},{"pmid":"11137213","id":"PMC_11137213","title":"Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G.","date":"2000","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11137213","citation_count":115,"is_preprint":false},{"pmid":"18946929","id":"PMC_18946929","title":"The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity.","date":"2008","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/18946929","citation_count":106,"is_preprint":false},{"pmid":"1618657","id":"PMC_1618657","title":"Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism.","date":"1992","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1618657","citation_count":106,"is_preprint":false},{"pmid":"36099881","id":"PMC_36099881","title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.","date":"2022","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36099881","citation_count":104,"is_preprint":false},{"pmid":"11920559","id":"PMC_11920559","title":"Human T cell receptor-mediated recognition of HLA-E.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11920559","citation_count":90,"is_preprint":false},{"pmid":"18339401","id":"PMC_18339401","title":"Subtle changes in peptide conformation profoundly affect recognition of the non-classical MHC class I molecule HLA-E by the CD94-NKG2 natural killer cell receptors.","date":"2008","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18339401","citation_count":88,"is_preprint":false},{"pmid":"32859121","id":"PMC_32859121","title":"SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32859121","citation_count":87,"is_preprint":false},{"pmid":"21800130","id":"PMC_21800130","title":"Clinical significance of the HLA-E and CD94/NKG2 interaction.","date":"2011","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/21800130","citation_count":81,"is_preprint":false},{"pmid":"20634877","id":"PMC_20634877","title":"The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20634877","citation_count":81,"is_preprint":false},{"pmid":"31213473","id":"PMC_31213473","title":"Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31213473","citation_count":80,"is_preprint":false},{"pmid":"30134159","id":"PMC_30134159","title":"Distinct HLA-E Peptide Complexes Modify Antibody-Driven Effector Functions of Adaptive NK Cells.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30134159","citation_count":77,"is_preprint":false},{"pmid":"27699181","id":"PMC_27699181","title":"Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious Diseases.","date":"2016","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/27699181","citation_count":75,"is_preprint":false},{"pmid":"10064069","id":"PMC_10064069","title":"Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10064069","citation_count":73,"is_preprint":false},{"pmid":"30087334","id":"PMC_30087334","title":"Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30087334","citation_count":73,"is_preprint":false},{"pmid":"16487601","id":"PMC_16487601","title":"The involvement of HLA-E and -F in pregnancy.","date":"2006","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16487601","citation_count":71,"is_preprint":false},{"pmid":"27589686","id":"PMC_27589686","title":"HLA-E expression and its clinical relevance in human renal cell carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27589686","citation_count":61,"is_preprint":false},{"pmid":"25413103","id":"PMC_25413103","title":"Clinical and immunological significance of HLA-E in stem cell transplantation and cancer.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/25413103","citation_count":58,"is_preprint":false},{"pmid":"37264229","id":"PMC_37264229","title":"HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37264229","citation_count":57,"is_preprint":false},{"pmid":"17257316","id":"PMC_17257316","title":"HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17257316","citation_count":57,"is_preprint":false},{"pmid":"16095487","id":"PMC_16095487","title":"HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading.","date":"2005","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/16095487","citation_count":57,"is_preprint":false},{"pmid":"38064568","id":"PMC_38064568","title":"Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38064568","citation_count":54,"is_preprint":false},{"pmid":"26382247","id":"PMC_26382247","title":"HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire.","date":"2015","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26382247","citation_count":54,"is_preprint":false},{"pmid":"36560403","id":"PMC_36560403","title":"Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer.","date":"2022","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/36560403","citation_count":53,"is_preprint":false},{"pmid":"33766848","id":"PMC_33766848","title":"HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33766848","citation_count":53,"is_preprint":false},{"pmid":"35235832","id":"PMC_35235832","title":"SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35235832","citation_count":53,"is_preprint":false},{"pmid":"31690066","id":"PMC_31690066","title":"Dimorphism of HLA-E and its Disease Association.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31690066","citation_count":49,"is_preprint":false},{"pmid":"32113130","id":"PMC_32113130","title":"The unconventional role of HLA-E: The road less traveled.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32113130","citation_count":48,"is_preprint":false},{"pmid":"16573557","id":"PMC_16573557","title":"HLA-E and immunobiology of pregnancy.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16573557","citation_count":47,"is_preprint":false},{"pmid":"17768067","id":"PMC_17768067","title":"Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?","date":"2007","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/17768067","citation_count":47,"is_preprint":false},{"pmid":"22947189","id":"PMC_22947189","title":"HLA-E expression in cervical adenocarcinomas: association with improved long-term survival.","date":"2012","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22947189","citation_count":46,"is_preprint":false},{"pmid":"19696636","id":"PMC_19696636","title":"Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation.","date":"2009","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19696636","citation_count":45,"is_preprint":false},{"pmid":"25862890","id":"PMC_25862890","title":"Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer.","date":"2015","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25862890","citation_count":44,"is_preprint":false},{"pmid":"15829309","id":"PMC_15829309","title":"An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15829309","citation_count":43,"is_preprint":false},{"pmid":"19860683","id":"PMC_19860683","title":"HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells.","date":"2009","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/19860683","citation_count":42,"is_preprint":false},{"pmid":"37140910","id":"PMC_37140910","title":"Intracellular trafficking of HLA-E and its regulation.","date":"2023","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37140910","citation_count":37,"is_preprint":false},{"pmid":"30386347","id":"PMC_30386347","title":"HLA-E Peptide Repertoire and Dimorphism-Centerpieces in the Adaptive NK Cell Puzzle?","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30386347","citation_count":37,"is_preprint":false},{"pmid":"39486805","id":"PMC_39486805","title":"Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39486805","citation_count":37,"is_preprint":false},{"pmid":"36477802","id":"PMC_36477802","title":"HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36477802","citation_count":37,"is_preprint":false},{"pmid":"36532006","id":"PMC_36532006","title":"Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36532006","citation_count":37,"is_preprint":false},{"pmid":"28676677","id":"PMC_28676677","title":"HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8+ T cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28676677","citation_count":37,"is_preprint":false},{"pmid":"27859015","id":"PMC_27859015","title":"HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.","date":"2016","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27859015","citation_count":37,"is_preprint":false},{"pmid":"30968409","id":"PMC_30968409","title":"HLA-E: exploiting pathogen-host interactions for vaccine development.","date":"2019","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30968409","citation_count":35,"is_preprint":false},{"pmid":"37675109","id":"PMC_37675109","title":"KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37675109","citation_count":35,"is_preprint":false},{"pmid":"31375574","id":"PMC_31375574","title":"Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.","date":"2019","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/31375574","citation_count":35,"is_preprint":false},{"pmid":"21186170","id":"PMC_21186170","title":"HLA-G and HLA-E in patients with juvenile idiopathic arthritis.","date":"2010","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21186170","citation_count":35,"is_preprint":false},{"pmid":"25401109","id":"PMC_25401109","title":"HLA-E: a novel player for histocompatibility.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25401109","citation_count":33,"is_preprint":false},{"pmid":"30172717","id":"PMC_30172717","title":"Identification of novel HIV-1-derived HLA-E-binding peptides.","date":"2018","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30172717","citation_count":33,"is_preprint":false},{"pmid":"32716529","id":"PMC_32716529","title":"Detailed and atypical HLA-E peptide binding motifs revealed by a novel peptide exchange binding assay.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32716529","citation_count":33,"is_preprint":false},{"pmid":"32961693","id":"PMC_32961693","title":"Human Amnion Epithelial Cells Impair T Cell Proliferation: The Role of HLA-G and HLA-E Molecules.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32961693","citation_count":33,"is_preprint":false},{"pmid":"37558657","id":"PMC_37558657","title":"High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37558657","citation_count":31,"is_preprint":false},{"pmid":"26310830","id":"PMC_26310830","title":"Regulation and trafficking of the HLA-E molecules during monocyte-macrophage differentiation.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26310830","citation_count":31,"is_preprint":false},{"pmid":"35596615","id":"PMC_35596615","title":"NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35596615","citation_count":31,"is_preprint":false},{"pmid":"17489859","id":"PMC_17489859","title":"Play it in E or G: utilization of HLA-E and -G in xenotransplantation.","date":"2007","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/17489859","citation_count":29,"is_preprint":false},{"pmid":"28127896","id":"PMC_28127896","title":"New insights in HLA-E polymorphism by refined analysis of the full-length gene.","date":"2017","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/28127896","citation_count":29,"is_preprint":false},{"pmid":"34228645","id":"PMC_34228645","title":"HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34228645","citation_count":28,"is_preprint":false},{"pmid":"19912639","id":"PMC_19912639","title":"HLA-E gene polymorphism associates with ankylosing spondylitis in Sardinia.","date":"2009","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19912639","citation_count":26,"is_preprint":false},{"pmid":"9154460","id":"PMC_9154460","title":"Description of a new HLA-E (E*01031) allele and its frequency in the Spanish population.","date":"1997","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9154460","citation_count":26,"is_preprint":false},{"pmid":"26916837","id":"PMC_26916837","title":"Expression of MHC class I-related molecules MICA, HLA-E and EPCR shape endothelial cells with unique functions in innate and adaptive immunity.","date":"2016","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26916837","citation_count":26,"is_preprint":false},{"pmid":"31009335","id":"PMC_31009335","title":"Enhancing Natural Killer and CD8+ T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8+ T Cells with HLA-E Monospecific Monoclonal Antibodies.","date":"2019","source":"Monoclonal antibodies in immunodiagnosis and immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31009335","citation_count":26,"is_preprint":false},{"pmid":"35347236","id":"PMC_35347236","title":"Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35347236","citation_count":24,"is_preprint":false},{"pmid":"23039207","id":"PMC_23039207","title":"Increased HLA-E expression in white matter lesions in multiple sclerosis.","date":"2012","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23039207","citation_count":24,"is_preprint":false},{"pmid":"28159587","id":"PMC_28159587","title":"Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas.","date":"2016","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/28159587","citation_count":23,"is_preprint":false},{"pmid":"32066399","id":"PMC_32066399","title":"HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival.","date":"2020","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32066399","citation_count":23,"is_preprint":false},{"pmid":"35705051","id":"PMC_35705051","title":"Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35705051","citation_count":23,"is_preprint":false},{"pmid":"37529053","id":"PMC_37529053","title":"Co-expression of HLA-E and HLA-G on genetically modified porcine endothelial cells attenuates human NK cell-mediated degranulation.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37529053","citation_count":23,"is_preprint":false},{"pmid":"22256791","id":"PMC_22256791","title":"HLA-E polymorphisms in hematopoietic stem cell transplantation.","date":"2012","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/22256791","citation_count":23,"is_preprint":false},{"pmid":"33893172","id":"PMC_33893172","title":"Natural killer cell receptors regulate responses of HLA-E-restricted T cells.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33893172","citation_count":22,"is_preprint":false},{"pmid":"35181585","id":"PMC_35181585","title":"HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.","date":"2022","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/35181585","citation_count":22,"is_preprint":false},{"pmid":"11212362","id":"PMC_11212362","title":"Detection of HLA-E and -G DNA alleles for population and disease studies.","date":"1999","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/11212362","citation_count":22,"is_preprint":false},{"pmid":"10887053","id":"PMC_10887053","title":"Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells.","date":"2000","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/10887053","citation_count":21,"is_preprint":false},{"pmid":"39753525","id":"PMC_39753525","title":"HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.","date":"2025","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/39753525","citation_count":20,"is_preprint":false},{"pmid":"37528310","id":"PMC_37528310","title":"XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37528310","citation_count":20,"is_preprint":false},{"pmid":"31445404","id":"PMC_31445404","title":"Capturing the antigen landscape: HLA-E, CD1 and MR1.","date":"2019","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31445404","citation_count":20,"is_preprint":false},{"pmid":"31697586","id":"PMC_31697586","title":"HLA-E-restricted CD8+ T Lymphocytes Efficiently Control Mycobacterium tuberculosis and HIV-1 Coinfection.","date":"2020","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31697586","citation_count":20,"is_preprint":false},{"pmid":"29499226","id":"PMC_29499226","title":"Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.","date":"2018","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29499226","citation_count":20,"is_preprint":false},{"pmid":"37390223","id":"PMC_37390223","title":"HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37390223","citation_count":20,"is_preprint":false},{"pmid":"27322426","id":"PMC_27322426","title":"Involvement of IL-10 and TGF-β in HLA-E-mediated neuroblastoma migration and invasion.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27322426","citation_count":20,"is_preprint":false},{"pmid":"26723902","id":"PMC_26723902","title":"Relevance of HLA-G, HLA-E and IL-10 expression in lip carcinogenesis.","date":"2015","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26723902","citation_count":19,"is_preprint":false},{"pmid":"26956431","id":"PMC_26956431","title":"HLA-E polymorphism and soluble HLA-E plasma levels in chronic hepatitis B patients.","date":"2016","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/26956431","citation_count":19,"is_preprint":false},{"pmid":"34201079","id":"PMC_34201079","title":"HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34201079","citation_count":19,"is_preprint":false},{"pmid":"38728394","id":"PMC_38728394","title":"CD8+ T cell targeting of tumor antigens presented by HLA-E.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38728394","citation_count":18,"is_preprint":false},{"pmid":"28946074","id":"PMC_28946074","title":"HLA-E regulatory and coding region variability and haplotypes in a Brazilian population sample.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28946074","citation_count":18,"is_preprint":false},{"pmid":"24144875","id":"PMC_24144875","title":"HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients.","date":"2013","source":"Multiple sclerosis (Houndmills, Basingstoke, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24144875","citation_count":18,"is_preprint":false},{"pmid":"39423821","id":"PMC_39423821","title":"Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39423821","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47875,"output_tokens":9716,"usd":0.144682,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20198,"output_tokens":9293,"usd":0.166657,"stage2_stop_reason":"end_turn"},"total_usd":0.311339,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"HLA-E binds to and is the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A, as well as CD94/NKG2B and CD94/NKG2C. HLA-E tetramers (recombinant HLA-E/β2m refolded with MHC leader-sequence peptide) bound specifically to CD94/NKG2A, NKG2B, and NKG2C on transfectants but not to KIR family receptors. Surface expression of HLA-E was sufficient to protect target cells from lysis by CD94/NKG2A+ NK cell clones.\",\n      \"method\": \"HLA-E tetramer binding assay, NK cell cytotoxicity assay, transfection of receptor-expressing cell lines\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional assays with tetramers and cytotoxicity, independently replicated in the same year by Lee et al. (PMID:9560253)\",\n      \"pmids\": [\"9486650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HLA-E is a major ligand for the NK cell inhibitory receptor CD94/NKG2A. Surface stabilization of HLA-E on .221 transfectants with appropriate HLA class I leader sequence peptides was sufficient to confer protection from CD94/NKG2A+ NK-mediated lysis. Neither the Ig-SF KIR receptors nor ILT2/LIR1 mediated this inhibitory effect. Anti-HLA-E, anti-CD94, or anti-CD94/NKG2A antibodies specifically restored NK lysis, confirming the HLA-E:CD94/NKG2A axis.\",\n      \"method\": \"NK cell cytotoxicity assay, antibody blocking, transfection of HLA class I allotypes into .221 cells, cold-loading of peptides\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (antibody blocking, peptide loading, NK cytotoxicity), replicates PMID:9486650\",\n      \"pmids\": [\"9560253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The peptide-binding groove of HLA-E is highly adapted for specific binding of conserved leader sequence peptides from HLA class Ia molecules and is structurally similar to class Ia MHC molecules but with higher specificity along the entire peptide length, unlike the promiscuous grooves of class Ia molecules.\",\n      \"method\": \"Structural analysis / crystallography (framework review)\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural description reported in a review citing crystallographic data; single source in this corpus for this structural claim\",\n      \"pmids\": [\"9700506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"HLA-E (originally designated HLA-6.2) encodes a protein that associates with β2-microglobulin, establishing it as an expressible MHC class I molecule. It maps between HLA-C and HLA-A on chromosome 6.\",\n      \"method\": \"Gene transfer into class I-null human lymphoblastoid cell line, immunoprecipitation to detect β2m association, deletion mutant mapping\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct gene transfer with protein detection, foundational identification paper\",\n      \"pmids\": [\"3260916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The two HLA-E alleles (HLA-E*0101 with Arg107 and HLA-E*0103 with Gly107) differ in peptide affinity, thermal stability, and cell surface expression levels. Crystal structures of HLA-E(G) complexed with two distinct peptides showed no significant conformational differences in the heavy chain between alleles or peptides, but differences in thermal stability and peptide affinity correlated with differential cell surface levels.\",\n      \"method\": \"Crystal structure determination, thermal stability assay, peptide affinity measurements, cell surface expression quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures plus multiple orthogonal biochemical assays (affinity, stability, surface expression) in one study\",\n      \"pmids\": [\"12411439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cell surface expression of HLA-E in mouse cells strictly requires coexpression of human β2-microglobulin. Soluble empty HLA-E/hβ2m complexes display low thermostability, indicating low-affinity β2m interaction contributes to inefficient peptide loading in the ER. The allelic substitution at position 107 (Gly or Arg) greatly affects intracellular transport and cell surface expression.\",\n      \"method\": \"Transfection of HLA-E ± human β2m into mouse myeloma cells, thermal stability assay, FACS quantification of surface expression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (transfection, stability, flow cytometry) establishing β2m dependency and allelic effects\",\n      \"pmids\": [\"10064069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Surface expression of HLA-E requires a functioning TAP molecule to transport HLA class I leader peptides into the ER. Without this peptide supply, HLA-E is unstable and degraded before reaching the cell surface. This mechanism allows NK cells to detect downregulation of classical HLA class I molecules in virally infected or tumor cells.\",\n      \"method\": \"Crystallographic studies and functional analyses described in review (citing original experimental work on TAP dependency)\",\n      \"journal\": \"Clinical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural and functional data cited from prior experimental work; review synthesis but based on original crystallographic and cell biology experiments\",\n      \"pmids\": [\"10887053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HLA-E is expressed on trophoblast cell surfaces and is recognized by the vast majority of decidual NK cells via CD94/NKG2 receptors. HLA-E tetramer binding to decidual NK cells is inhibited by anti-CD94 antibody. The functional consequence of this interaction is inhibition of decidual NK cell cytotoxicity.\",\n      \"method\": \"HLA-E tetramer staining of decidual NK cells, anti-CD94 antibody blocking, cytotoxicity assays with polyclonal decidual NK cells, immunostaining of trophoblast\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tetramer staining, antibody blocking, and functional cytotoxicity assays in primary cells\",\n      \"pmids\": [\"10898498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HLA-E transcription is induced by IFN-γ through an upstream STAT1 binding site and is inducible by CIITA through the SXY regulatory module. HLA-E is not inducible by NF-κB or IRF1 due to divergence in its promoter regulatory elements.\",\n      \"method\": \"Promoter analysis, transcriptional reporter assays, cis-acting element mapping\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter functional analysis with defined binding sites, single lab\",\n      \"pmids\": [\"11137213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"HLA-E can be recognized by the αβ T cell receptor (TCR) on CD8+ T cells independently of CD94/NKG2C. An αβ CD8+CD94/NKG2C+ CTL clone recognized RMA-S/HLA-E cells loaded with specific HLA class I leader sequence peptides and also a peptide derived from EBV BZLF-1 protein. Anti-clonotypic TCR antibody blocked lysis while anti-CD94 did not, and HLA-E tetramers stained K14 cells in a TCR-dependent manner.\",\n      \"method\": \"CTL cytotoxicity assay, antibody blocking with anti-TCR and anti-CD94, HLA-E tetramer staining\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (cytotoxicity, antibody blocking, tetramer staining) establishing TCR-dependent HLA-E recognition\",\n      \"pmids\": [\"11920559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HLA-E cell surface expression in tumor cell lines is related to the availability of free β2-microglobulin in the cytoplasm. Tumor cells with downregulation of HLA class Ia heavy chains (leading to excess β2m) show increased HLA-E surface expression. Addition of human β2m to tumor cells expressing HLA-E(G) allele increased HLA-E surface expression. Total loss of HLA class Ia expression (including β2m mutations) abolished HLA-E surface expression.\",\n      \"method\": \"Monoclonal antibody staining (3D12) of tumor cell lines, exogenous β2m addition experiments, analysis of cell lines with defined HLA alterations\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab with multiple cell line contexts and β2m supplementation experiments\",\n      \"pmids\": [\"12618909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Inhibitory NKG2A/CD94 and activating NKG2E/CD94 receptors bind HLA-E with indistinguishable affinities, both higher than the activating NKG2C/CD94 receptor. The peptide presented by HLA-E significantly influences binding affinity of all three receptors, while HLA-E allelic differences (position 107) had no effect on receptor binding affinity.\",\n      \"method\": \"Quantitative binding affinity measurements and thermodynamic analysis (surface plasmon resonance or equivalent) for three NKG2x/CD94 receptors with HLA-E/peptide complexes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biophysical affinity measurements with multiple receptor-ligand combinations, peptide variation systematically tested\",\n      \"pmids\": [\"15728498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Stable surface expression of HLA-E on porcine cells requires appropriate peptide loading (HLA class I leader sequence peptides). HLA-E expression on porcine cells protected them from lysis by human NKG2A+ NK clones. An HLA-E single-chain trimer (SCT) fusing β2m, peptide, and HLA-E heavy chain was engineered and demonstrated correct folding and function, inhibiting NK cytotoxicity and IFN-γ secretion.\",\n      \"method\": \"Transfection of porcine cell lines, FACS for surface expression, NK cytotoxicity assay, IFN-γ measurement, engineering of single-chain trimer construct\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional cytotoxicity assays in transfected porcine cells, SCT reconstitution validates peptide-dependent HLA-E function\",\n      \"pmids\": [\"15829309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TNFα, IL-1β, and IFN-γ upregulate cell-surface HLA-E expression on endothelial cells and induce release of soluble HLA-E (sHLA-E). HLA-E upregulation protects IFN-γ-activated endothelial cells from NK-mediated lysis, while sHLA-E protects bystander cells. HLA-E protein expression in normal human non-lymphoid organs is mainly restricted to endothelial cells.\",\n      \"method\": \"In vitro cytokine stimulation of endothelial cells, flow cytometry for surface HLA-E, NK cell cytotoxicity assay, ELISA for sHLA-E\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cytokine stimulation conditions, cytotoxicity functional readout, sHLA-E quantification; two orthogonal functional outcomes\",\n      \"pmids\": [\"17179229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structures of HLA-E complexed with two leader peptides (HLA-Cw*07: VMAPRALLL and HLA-G*01: VMAPRTLFL, both at 2.5 Å resolution) showed that allotypic variations in leader sequences do not cause conformational changes in the HLA-E heavy chain, but subtle changes in peptide conformation within the binding groove profoundly affect recognition by CD94-NKG2 receptors. HLA-Cw*07 peptide (poorly recognized) versus HLA-G*01 peptide (high-affinity ligand) differ in conformation within the groove.\",\n      \"method\": \"X-ray crystallography at 2.5 Å resolution, structural comparison of peptide-HLA-E complexes\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two crystal structures determined and compared, mechanistic conclusion about peptide conformation and receptor recognition\",\n      \"pmids\": [\"18339401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HLA-E expressed on gynecological tumors inhibits CD8+ T cell (CTL) function via CD94/NKG2A receptor interaction. Up to 50% of intraepithelial CTLs expressed the inhibitory CD94/NKG2A receptor. In ovarian cancer, high HLA-E expression completely neutralized the beneficial effect of high CTL infiltration on overall survival, indicating functional inhibition of CTLs by HLA-E:NKG2A interaction in the tumor microenvironment.\",\n      \"method\": \"Immunohistochemistry on 420 tumor sections, in situ detection of NKG2A+ CTLs, survival analysis linked to HLA-E expression and CTL infiltration\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — large tumor cohort with in situ co-localization; functional inhibition inferred from survival data rather than direct in vitro blocking\",\n      \"pmids\": [\"21670276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HCMV-driven expansion of NKG2C+ NK cells requires CD94/NKG2C:HLA-E axis and IL-12 from CD14+ monocytes. Blockade of CD94/NKG2C on NK cells or silencing of HLA-E in HCMV-infected fibroblasts greatly impaired expansion of NKG2C+ NK cells. IL-12 neutralization substantially reduced CD25 upregulation and NKG2C+ subset expansion.\",\n      \"method\": \"NK-monocyte coculture system, NKG2C blockade antibodies, HLA-E siRNA knockdown in infected fibroblasts, IL-12 neutralization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal knockdown and blocking experiments in a mechanistically defined coculture system\",\n      \"pmids\": [\"25384219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"HLA-E:NKG2A interaction inhibited degranulation of NKG2A+ NK cell subsets with almost all tested peptides. In contrast, NKG2A-NKG2C+ NK cell responses were enhanced only by a restricted set of peptides, most strongly by the HLA-G leader peptide. The HLA-E:G-peptide complex triggered NKG2C receptor internalization (reduced by bafilomycin, indicating lysosomal pathway involvement).\",\n      \"method\": \"NK cell degranulation assay (CD107a expression), peptide-induced HLA-E surface expression on PBMCs, NKG2C receptor internalization assay with bafilomycin\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional degranulation assays with peptide panel and mechanistic follow-up on receptor internalization; single lab\",\n      \"pmids\": [\"26382247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"During monocyte-to-macrophage differentiation, newly synthesized HLA-E molecules are primarily trafficked to intracellular autophagy-lysosomal vesicles (colocalizing with LC3 and LAMP1) rather than the cell surface, unlike classical HLA class I. Only a small fraction of HLA-E reaches the cell surface, and NK lysis is still inhibited by anti-NKG2A antibody comparably in differentiated and undifferentiated cells.\",\n      \"method\": \"Confocal microscopy with LC3 and LAMP1 co-localization, subcellular fractionation, flow cytometry, NK cytotoxicity assay in monocytic cell lines and primary monocytes\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct imaging colocalization with functional markers, multiple cell contexts; single lab\",\n      \"pmids\": [\"26310830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of HLA-E bound to HIV- and Mtb-derived pathogen peptides reveal that despite preferences for canonical primary anchor residues, HLA-E-bound pathogen peptides can adopt alternative conformations within the peptide-binding groove. Combined structural and mutagenesis analyses show greater tolerance for hydrophobic and polar residues in the primary pockets than previously appreciated.\",\n      \"method\": \"X-ray crystallography of HLA-E/peptide complexes, mutagenesis of binding pockets, biochemical peptide binding studies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures plus mutagenesis and biochemical binding data in one study\",\n      \"pmids\": [\"30087334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Adaptive NK cells recognize differences between HLA-E-peptide complexes with exquisite specificity via the activating CD94/NKG2C receptor. Prolonged exposure to HLA-E presenting the HLA-G leader peptide VMAPRTLFL enriched adaptive NK cells with low FcεRγ expression, upregulated CD25, increased proliferation, and elevated antibody-dependent cellular cytotoxicity and IFN-γ responses compared to other HLA-E peptide complexes.\",\n      \"method\": \"NK cell coculture with defined HLA-E peptide complexes, flow cytometry for phenotype markers, functional assays for ADCC and IFN-γ, CD25/FcεRγ expression analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic peptide panel comparison with multiple functional readouts; direct functional consequence of specific HLA-E:peptide complex established\",\n      \"pmids\": [\"30134159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HLA-E presents glycopeptides from the Mycobacterium tuberculosis protein MPT32 to CD8+ T cells. Recognition by an HLA-E-restricted CD8+ T cell clone required N-terminal O-linked mannosylation of MPT32 by a mannosyltransferase encoded by Rv1002c, establishing the first post-translationally modified Mtb antigen presented by HLA-E.\",\n      \"method\": \"T cell clone cytotoxicity/recognition assay, HLA-E tetramer staining, Rv1002c mannosyltransferase mutant bacteria, glycopeptide synthesis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — T cell clone recognition with mannosyltransferase mutant establishing PTM requirement; single lab\",\n      \"pmids\": [\"28676677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Senescent dermal fibroblasts upregulate HLA-E expression, and this HLA-E interacts with the inhibitory receptor NKG2A on NK cells and highly differentiated CD8+ T cells to inhibit immune responses against senescent cells. HLA-E induction in senescent cells is driven by SASP-related pro-inflammatory cytokines and regulated by p38 MAP kinase signaling in vitro. Blocking HLA-E:NKG2A interaction boosted immune responses against senescent cells in vitro.\",\n      \"method\": \"Senescence induction in primary fibroblasts, flow cytometry for HLA-E expression, NK/CD8 T cell killing assay, p38 inhibitor treatment, NKG2A blocking antibody\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (p38 inhibitor, cytokines, NKG2A blockade) with defined functional readout of immune killing\",\n      \"pmids\": [\"31160572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIV-1 Nef protein downmodulates HLA-E surface levels on infected primary CD4+ T cells by targeting the cytoplasmic tail of HLA-E. Tail-swap experiments exchanging the cytoplasmic tail of HLA-A2 with that of HLA-E demonstrated Nef specifically targets the HLA-E cytoplasmic tail. HIV-1 mutants lacking functional Nef (and to a lesser extent Vpu) showed impaired HLA-E downmodulation.\",\n      \"method\": \"Primary HIV-1 strain infection of CD4+ T cells, single Nef/Vpu expression in T cell lines, cytoplasmic tail swap constructs (HLA-A2/HLA-E chimeras), flow cytometry\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tail swap mutagenesis plus multiple viral mutant analyses establishing Nef as the effector targeting the HLA-E cytoplasmic tail\",\n      \"pmids\": [\"31375574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SARS-CoV-2 spike 1 protein (SP1) expressed intracellularly in lung epithelial cells induces HLA-E surface expression via presentation of an SP1-derived HLA-E-binding peptide, leading to increased NKG2A/CD94 expression on NK cells and reduced NK cell degranulation via HLA-E/NKG2A interaction. The GATA3 transcription factor was ruled out as responsible for HLA-E upregulation.\",\n      \"method\": \"Transfection of lung epithelial cells with SARS-CoV-2 spike constructs, flow cytometry for HLA-E and NK cell activation markers, NK cell co-culture assay, immunofluorescence, GATA3 inhibitor experiments\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cell transfection with functional NK readout; single lab; peptide identification supporting HLA-E upregulation mechanism\",\n      \"pmids\": [\"32859121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HLA-E-restricted HIV-1-specific CD8+ T cell clones and allogeneic CD8+ T cells transduced with their TCRs suppressed HIV-1 replication in CD4+ T cells in vitro. HLA-E-restricted T cells were primed in vitro and recognized Gag-derived peptides presented by HLA-E.\",\n      \"method\": \"In vitro T cell priming, TCR transduction into allogeneic CD8+ T cells, HIV-1 replication suppression assay in CD4+ T cells\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — TCR transduction establishing antigen specificity, functional suppression of viral replication as direct readout\",\n      \"pmids\": [\"33766848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The SARS-CoV-2 Non-structural protein 13 (Nsp13) encodes a peptide presented by HLA-E that prevents binding of HLA-E to the inhibitory receptor NKG2A (unlike self-peptides), rendering target cells susceptible to NKG2A-expressing NK cell attack. NKG2A+ NK cells were specifically activated and proficiently limited SARS-CoV-2 replication in infected lung epithelial cells in vitro.\",\n      \"method\": \"Peptide-HLA-E binding assay, NKG2A blocking experiments, NK cell activation assay, viral replication suppression assay in lung epithelial cells, patient NK cell phenotyping\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal assays (peptide binding, NKG2A blocking, NK activation, viral replication) establishing viral peptide-HLA-E-NKG2A mechanism\",\n      \"pmids\": [\"35235832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structures of HLA-E bound to VL9 (MHC class Ia signal peptides) versus pathogen-derived peptides reveal that VL9 positions close to the α2 helix via three HLA-E-exclusive amino acids. Non-VL9 pathogen peptides introduce an alternative peptide-binding motif and re-configure a key TCR-interacting α2 region, providing the structural basis for VL9- versus non-VL9-HLA-E immune discrimination. Small-angle X-ray scattering revealed that non-VL9 HLA-E complexes are conformationally dynamic in solution compared to VL9 complexes.\",\n      \"method\": \"X-ray crystallography of multiple HLA-E/peptide complexes, small-angle X-ray scattering (SAXS), mutagenesis of key residues, peptide excess experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures plus SAXS solution data, mutagenesis, establishing distinct structural bases for VL9 vs. non-VL9 binding\",\n      \"pmids\": [\"35705051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Among 16 common classical HLA class I signal peptide variants, only 6 can be efficiently processed to generate epitopes enabling CD94/NKG2 engagement ('functional SPs'). The single functional HLA-B SP (HLA-B/-21M) induces high HLA-E expression but provides the lowest NKG2 receptor recognition, and competes with other SPs for providing epitope to HLA-E, thereby reducing overall CD94/NKG2A recognition of target cells.\",\n      \"method\": \"Systematic quantitative analysis of 16 SP variants for HLA-E stabilization and CD94/NKG2A/C binding, competitive peptide loading assays, NK cell functional assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic quantitative screen of all major SP variants with functional NK assays and competition experiments; multiple orthogonal approaches\",\n      \"pmids\": [\"37264229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLA-E is largely retained in the endoplasmic reticulum after synthesis due to limited supply of high-affinity peptides, with further fine-tuning by its cytoplasmic tail. Once at the cell surface, HLA-E is unstable and rapidly internalized; its cytoplasmic tail is required for HLA-E internalization, resulting in enrichment in late and recycling endosomes. This distinguishes HLA-E trafficking from classical HLA class I.\",\n      \"method\": \"Live cell imaging, FRAP, subcellular fractionation, cytoplasmic tail deletion/mutation constructs, trafficking inhibitor studies, comparison with classical HLA class I\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live imaging and tail mutagenesis with multiple orthogonal methods defining HLA-E intracellular transport pathway\",\n      \"pmids\": [\"37140910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLA-E presents EBV LMP-1-derived peptides (GGDPHLPTL or GGDPPLPTL) to NKG2A+ NK and CD8+ T cells in an inhibitory manner. EBV strains encoding both peptide variants were associated with symptomatic EBV reactivations. The highly expressed HLA-E*0103/0103 genotype is protective against infectious mononucleosis through induction of BZLF1-specific HLA-E-restricted CD8+ T cell responses that efficiently prevent viral dissemination in vitro.\",\n      \"method\": \"Functional NK and CD8+ T cell assays, viral dissemination assay in vitro, large cohort study (1404 patients), peptide-HLA-E binding experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional in vitro viral suppression assays combined with large clinical cohort; mechanistic NKG2A/LMP-1/HLA-E axis defined\",\n      \"pmids\": [\"36477802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Platelet-derived RGS18 promotes HLA-E expression on circulating tumor cells (CTCs) through the AKT-GSK3β-CREB signaling pathway, enabling CTCs to evade NK cell-mediated immune surveillance via the HLA-E:CD94-NKG2A immune checkpoint. Disruption of this interaction by NKG2A blockade or HLA-E knockdown enhanced NK-mediated killing in vitro and prevented tumor metastasis in vivo.\",\n      \"method\": \"Single-cell transcriptomics, in vitro NK killing assay, in vivo tumor metastasis mouse model, HLA-E knockdown, NKG2A blockade, RGS18 overexpression/knockdown with AKT/GSK3β/CREB pathway analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vitro and in vivo experiments establishing RGS18-AKT-GSK3β-CREB-HLA-E pathway with functional NK and metastasis readouts\",\n      \"pmids\": [\"36706761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Antigen-specific human NK cell memory against HIV and influenza is mediated largely through the activating CD94/NKG2C receptor recognizing HLA-E in an epitope-specific manner. Single-cell cloning validated permanent antigen specificity of individual memory NK cells. KLRG1, α4β7, and NKG2C were identified as biomarkers of antigen-specific NK memory, and individual HLA-E-restricted peptides from HIV-1 and influenza constitute dominant NK cell responses in infected persons.\",\n      \"method\": \"Single-cell cloning of NK cells, HLA-E tetramer staining, NKG2C blocking, peptide-HLA-E binding assays, immunophenotyping of infected patient NK cells\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-cell cloning establishing antigen specificity, NKG2C blocking, HLA-E tetramers; multiple orthogonal methods\",\n      \"pmids\": [\"38064568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"High-throughput yeast-display screening identified 500 unique peptides that bind both HLA-E and CD94/NKG2A or CD94/NKG2C, including CMV proteome-derived peptides. Peptides selectively activating NKG2C+ NK cells were identified. Prediction algorithms trained on yeast-display selections identified human and CMV proteome-derived HLA-E-presented peptides capable of signaling through both inhibitory and activating receptors.\",\n      \"method\": \"Yeast-displayed peptide library screen, HLA-E/CD94/NKG2x binding selection, NK cell functional assays, machine learning-based prediction algorithm\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large-scale functional screen with direct NK cell activation readouts, multiple validation experiments\",\n      \"pmids\": [\"37558657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HLA-E-restricted CD8+ T cells from CMV-infected individuals express inhibitory KIR2DL1 and KIR2DL2/L3 when bearing high-affinity TCRs for HLA-E/self-peptide, while T cells with lower-affinity TCRs expressed the activating receptor NKG2C. Activation of high-affinity TCR-bearing T cells was regulated by KIR2D receptor interaction with HLA-C, providing a mechanism for self/non-self discrimination by HLA-E-restricted T cells.\",\n      \"method\": \"RNA sequencing, flow cytometry, TCR affinity measurement, KIR2D blocking experiments, CMV UL40/HLA-E tetramer staining\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — TCR affinity correlation with NKR expression, KIR blocking establishing functional regulation; multiple orthogonal approaches\",\n      \"pmids\": [\"33893172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HLA-E-restricted SARS-CoV-2-specific CD8+ T cell clones with diverse TCRs recognized five SARS-CoV-2-derived peptides presented by HLA-E and suppressed viral replication in Calu-3 lung epithelial cells. SARS-CoV-2 infection markedly downregulated classical HLA class I (HLA-A, B, C) expression while HLA-E expression was not affected, enabling continued HLA-E-restricted T cell recognition.\",\n      \"method\": \"T cell clone isolation and characterization, HLA-E peptide-specific suppression of SARS-CoV-2 replication, flow cytometry for HLA class I and HLA-E surface expression in infected cells, primary reconstituted human airway epithelial cells\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — T cell clone functional suppression assay, infection-induced HLA class I modulation measured in primary and cell line models\",\n      \"pmids\": [\"37390223\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HLA-E is a minimally polymorphic, non-classical MHC class I molecule that assembles as a β2-microglobulin-associated trimer requiring high-affinity peptides (predominantly nonameric leader-sequence peptides, VL9, derived from classical HLA-A/B/C/G signal sequences) for stable cell-surface expression; at the surface it primarily engages CD94/NKG2A (inhibitory) and CD94/NKG2C (activating) receptors on NK cells and T cell subsets to regulate cytotoxicity, with the peptide identity and conformation within the HLA-E groove critically determining receptor binding affinity and functional outcome; HLA-E is largely ER-retained due to limited high-affinity peptide availability, its cytoplasmic tail facilitates rapid surface internalization into late/recycling endosomes, its expression is transcriptionally induced by IFN-γ (via STAT1) and CIITA but not NF-κB or IRF1, and it can also present lower-affinity pathogen-derived peptides to αβ TCR-bearing CD8+ T cells, enabling both innate immune surveillance and adaptive anti-pathogen responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HLA-E is a non-classical MHC class I molecule that functions as a central sensor of cellular integrity, assembling as a β2-microglobulin-associated complex that requires high-affinity peptide loading—predominantly nonameric leader-sequence (VL9) peptides derived from classical HLA class Ia and HLA-G signal sequences—for stable cell-surface expression [#3, #2, #28]. Surface stabilization is strictly dependent on β2-microglobulin availability, TAP-mediated transport of leader peptides into the ER, and the allelic identity at position 107 governing thermal stability and surface levels [#5, #6, #4, #10]. At the cell surface, HLA-E primarily engages the CD94/NKG2 receptor family on NK cells and T cell subsets: it is the dominant ligand for the inhibitory CD94/NKG2A receptor, whose engagement protects target cells from NK-mediated lysis, and for the activating CD94/NKG2C receptor, with the receptor-bound outcome dictated by the precise conformation of the peptide within the binding groove rather than by heavy-chain allelic differences [#0, #1, #11, #14]. Because peptide supply links HLA-E surface display to the status of classical class I expression, this axis allows NK cells to detect downregulation of HLA class Ia in infected or transformed cells [#6, #10]. HLA-E additionally presents lower-affinity pathogen-derived peptides—from HCMV, EBV, HIV, Mycobacterium tuberculosis, and SARS-CoV-2—to αβ TCR-bearing CD8+ T cells and to adaptive/memory NK cells, with non-VL9 peptides adopting alternative groove conformations that reconfigure the receptor- and TCR-interacting α2 region [#9, #27, #21, #25, #26, #32, #35]. HLA-E trafficking is distinct from classical class I: limited high-affinity peptide causes ER retention, and its cytoplasmic tail drives rapid surface internalization into late and recycling endosomes, a feature exploited by HIV-1 Nef to downmodulate surface HLA-E [#29, #23, #18]. Its expression is transcriptionally induced by IFN-γ via STAT1 and by CIITA, but not by NF-κB or IRF1, and is upregulated on endothelial cells, senescent cells, and tumor cells where the HLA-E:NKG2A interaction acts as an immune checkpoint suppressing NK and CTL responses [#8, #13, #22, #15, #31].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established that the HLA-E locus encodes a genuinely expressible MHC class I protein rather than a pseudogene, fixing it as a candidate immune molecule.\",\n      \"evidence\": \"gene transfer into class I-null lymphoblastoid cells with immunoprecipitation detecting β2m association, and deletion mapping on chromosome 6\",\n      \"pmids\": [\"3260916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define what peptides HLA-E presents\", \"No receptor or functional role identified\", \"Tissue distribution and induction unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the core function of HLA-E by showing it is the predominant ligand for CD94/NKG2 receptors and that its surface display inhibits NK cytotoxicity, explaining how missing-self surveillance is licensed.\",\n      \"evidence\": \"HLA-E tetramer binding to NKG2A/B/C transfectants, peptide-loaded .221 transfectants, antibody blocking, and NK cytotoxicity assays\",\n      \"pmids\": [\"9486650\", \"9560253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify differential affinities of activating vs inhibitory receptors\", \"Structural basis of peptide-dependent recognition unresolved\", \"Did not address TCR-mediated recognition\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed the HLA-E groove is uniquely specialized for conserved leader-sequence peptides with high specificity along the entire peptide, distinguishing it from promiscuous class Ia molecules.\",\n      \"evidence\": \"structural analysis citing crystallographic data (review framework)\",\n      \"pmids\": [\"9700506\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single review-derived structural claim in this corpus\", \"Did not establish which peptide features control receptor recognition\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linked HLA-E surface expression to the TAP peptide-supply pathway, establishing the mechanistic logic by which NK cells sense loss of classical class I presentation.\",\n      \"evidence\": \"review synthesis of crystallographic and cell-biology experiments on TAP dependency\",\n      \"pmids\": [\"10887053\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review synthesis rather than primary data in this entry\", \"Quantitative peptide affinity thresholds not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated that β2-microglobulin availability and the position-107 allelic substitution govern HLA-E assembly, transport, and surface levels, identifying biochemical bottlenecks in its display.\",\n      \"evidence\": \"transfection of HLA-E ± human β2m into mouse myeloma cells with thermal stability assays and FACS quantification\",\n      \"pmids\": [\"10064069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect surface levels to receptor recognition outcomes\", \"In vivo relevance of allelic effect untested here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended HLA-E function to a physiological context by showing trophoblast HLA-E inhibits decidual NK cytotoxicity via CD94/NKG2, implicating it in maternal-fetal tolerance.\",\n      \"evidence\": \"HLA-E tetramer staining of decidual NK cells, anti-CD94 blocking, and primary-cell cytotoxicity assays\",\n      \"pmids\": [\"10898498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the in vivo peptide presented by trophoblast HLA-E\", \"Did not address activating receptor outcomes\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified the transcriptional control of HLA-E, showing IFN-γ/STAT1 and CIITA induction but insensitivity to NF-κB and IRF1, distinguishing its regulation from inflammatory induction.\",\n      \"evidence\": \"promoter reporter assays and cis-element mapping\",\n      \"pmids\": [\"11137213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab promoter analysis\", \"Did not characterize regulation in primary tissue contexts\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed that HLA-E allelic variants differ in peptide affinity and stability but adopt indistinguishable heavy-chain conformations, separating expression-level effects from structural effects.\",\n      \"evidence\": \"crystal structures of HLA-E(G) with two peptides plus thermal stability, affinity, and surface expression measurements\",\n      \"pmids\": [\"12411439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test receptor-binding consequences of allelic differences directly\", \"Peptide repertoire breadth not assessed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established a second recognition arm by showing HLA-E can be recognized directly by αβ TCRs on CD8+ T cells independently of CD94/NKG2C, including a viral (EBV BZLF-1) peptide.\",\n      \"evidence\": \"CTL cytotoxicity with anti-TCR vs anti-CD94 blocking and TCR-dependent HLA-E tetramer staining\",\n      \"pmids\": [\"11920559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TCR diversity and peptide breadth not defined\", \"In vivo protective role untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected HLA-E surface levels to free cytoplasmic β2m in tumor cells, showing class Ia downregulation can paradoxically raise HLA-E and shape NK evasion.\",\n      \"evidence\": \"antibody staining of tumor lines with defined HLA alterations and exogenous β2m supplementation\",\n      \"pmids\": [\"12618909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab correlative cell-line study\", \"Functional NK outcome of increased HLA-E not directly tested here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Quantified the biophysical hierarchy of CD94/NKG2 receptor binding and demonstrated peptide identity—not allelic variation—controls receptor affinity, defining the molecular tuning of HLA-E signalling.\",\n      \"evidence\": \"quantitative affinity and thermodynamic measurements for NKG2A/C/E with HLA-E/peptide complexes\",\n      \"pmids\": [\"15728498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how peptide alters the recognition interface structurally\", \"Functional NK consequences inferred not directly measured here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Validated peptide-dependent HLA-E function in a xenogeneic context and engineered a single-chain trimer, providing a reagent and proof that loaded HLA-E suffices to inhibit NK responses.\",\n      \"evidence\": \"porcine cell transfection, NK cytotoxicity and IFN-γ assays, and single-chain β2m-peptide-HLA-E construct\",\n      \"pmids\": [\"15829309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SCT may not capture native conformational dynamics\", \"Restricted to inhibitory receptor readouts\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated cytokine-driven HLA-E upregulation on endothelium and release of soluble HLA-E, extending its immunomodulatory reach to bystander protection.\",\n      \"evidence\": \"cytokine stimulation of endothelial cells, flow cytometry, NK cytotoxicity, and sHLA-E ELISA\",\n      \"pmids\": [\"17179229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of sHLA-E generation not defined\", \"In vivo significance of soluble form untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided the structural basis for differential receptor recognition by showing subtle peptide conformational changes in the groove—not heavy-chain changes—dictate CD94/NKG2 binding.\",\n      \"evidence\": \"X-ray crystallography of HLA-E with HLA-Cw*07 and HLA-G*01 leader peptides at 2.5 Å\",\n      \"pmids\": [\"18339401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Limited to two leader peptides\", \"Did not address pathogen-peptide conformations\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed HLA-E:NKG2A acts as a functional checkpoint in tumors, neutralizing the survival benefit of CTL infiltration and implicating it in cancer immune evasion.\",\n      \"evidence\": \"immunohistochemistry on 420 tumor sections with in situ NKG2A+ CTL detection and survival analysis\",\n      \"pmids\": [\"21670276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional inhibition inferred from survival rather than direct in vitro blocking\", \"Peptides presented in tumor context not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the HLA-E:NKG2C axis as a driver of HCMV-induced adaptive NK cell expansion requiring monocyte-derived IL-12, linking HLA-E to NK memory formation.\",\n      \"evidence\": \"NK-monocyte coculture, NKG2C blockade, HLA-E siRNA in infected fibroblasts, and IL-12 neutralization\",\n      \"pmids\": [\"25384219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HLA-E peptide driving expansion not pinpointed here\", \"Durability of memory not assessed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Distinguished the peptide selectivity of inhibitory versus activating signalling, showing nearly all peptides inhibit via NKG2A while only restricted peptides (notably HLA-G leader) activate NKG2C, with HLA-E:G triggering lysosomal NKG2C internalization.\",\n      \"evidence\": \"degranulation (CD107a) assays with a peptide panel and bafilomycin-sensitive NKG2C internalization assays\",\n      \"pmids\": [\"26382247\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab functional dataset\", \"Structural basis of activating peptide selectivity not resolved here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed that during macrophage differentiation HLA-E is preferentially routed into autophagy-lysosomal vesicles rather than the surface, indicating cell-state-specific trafficking control.\",\n      \"evidence\": \"confocal LC3/LAMP1 colocalization, subcellular fractionation, flow cytometry, and NK cytotoxicity in monocytic cells\",\n      \"pmids\": [\"26310830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional purpose of intracellular HLA-E pool unclear\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed HLA-E can present post-translationally modified (O-mannosylated) mycobacterial glycopeptides to CD8+ T cells, expanding the chemical space of HLA-E antigens.\",\n      \"evidence\": \"T cell clone recognition assays, HLA-E tetramers, Rv1002c mannosyltransferase mutant bacteria, and synthetic glycopeptides\",\n      \"pmids\": [\"28676677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single clone/single-lab evidence\", \"In vivo protective relevance untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated structurally that pathogen-derived peptides occupy the HLA-E groove with greater anchor-residue tolerance and alternative conformations than canonical VL9, broadening the predicted HLA-E pathogen peptidome.\",\n      \"evidence\": \"X-ray crystallography of HLA-E/HIV and Mtb peptide complexes with pocket mutagenesis and binding studies\",\n      \"pmids\": [\"30087334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor/TCR consequences of these conformations not directly measured here\", \"Limited peptide set\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed adaptive NK cells discriminate HLA-E peptide complexes with exquisite specificity via NKG2C, with the HLA-G leader peptide selectively enriching functionally superior adaptive NK cells.\",\n      \"evidence\": \"NK coculture with defined HLA-E peptide complexes, phenotyping, and ADCC/IFN-γ functional assays\",\n      \"pmids\": [\"30134159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of peptide-specific NKG2C licensing not resolved here\", \"In vivo selection dynamics untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified HLA-E as an immune-evasion signal on senescent cells driven by SASP cytokines and p38 MAPK, inhibiting NK and CD8 clearance via NKG2A.\",\n      \"evidence\": \"senescence induction in fibroblasts, HLA-E flow cytometry, killing assays, p38 inhibition, and NKG2A blockade\",\n      \"pmids\": [\"31160572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide presented by senescent HLA-E not identified\", \"In vivo senescent-cell clearance not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped HIV-1 Nef-mediated HLA-E downmodulation to the HLA-E cytoplasmic tail, revealing a virus-driven manipulation of HLA-E surface display.\",\n      \"evidence\": \"primary HIV-1 infection of CD4+ T cells, single Nef/Vpu expression, and HLA-A2/HLA-E tail-swap chimeras with flow cytometry\",\n      \"pmids\": [\"31375574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking machinery engaged by Nef not defined here\", \"Net effect on NK vs T cell recognition in vivo unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed SARS-CoV-2 spike-derived peptide induces HLA-E surface display and suppresses NK degranulation via NKG2A, an early inhibitory immune-evasion mechanism.\",\n      \"evidence\": \"spike construct transfection of lung epithelial cells, NK coculture, immunofluorescence, and GATA3 inhibition\",\n      \"pmids\": [\"32859121\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Transcriptional driver of HLA-E upregulation not positively identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated HLA-E-restricted, HIV Gag-specific CD8+ T cells can suppress viral replication and that their TCRs are transferable, establishing therapeutic potential for HLA-E-restricted T cells.\",\n      \"evidence\": \"in vitro T cell priming, TCR transduction into allogeneic CD8+ T cells, and HIV-1 replication suppression assays\",\n      \"pmids\": [\"33766848\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy untested\", \"Breadth of protective epitopes limited\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a self/non-self discrimination mechanism in which TCR affinity for HLA-E/self-peptide dictates KIR2D versus NKG2C receptor expression on HLA-E-restricted T cells, regulating their activation via HLA-C.\",\n      \"evidence\": \"RNA-seq, TCR affinity measurement, KIR2D blocking, and CMV UL40/HLA-E tetramer staining\",\n      \"pmids\": [\"33893172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across antigens not established\", \"In vivo regulatory consequences untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the structural rationale for VL9 versus non-VL9 discrimination, showing pathogen peptides reconfigure the TCR-interacting α2 region and make non-VL9 HLA-E complexes conformationally dynamic.\",\n      \"evidence\": \"multiple crystal structures, SAXS solution analysis, and mutagenesis of HLA-E-exclusive residues\",\n      \"pmids\": [\"35705051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional receptor outcomes of dynamic complexes not directly quantified here\", \"Limited to selected peptides\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified a SARS-CoV-2 Nsp13 peptide that, unlike self-peptides, blocks HLA-E:NKG2A engagement and thereby sensitizes infected cells to NKG2A+ NK attack, defining a peptide-driven activating mechanism.\",\n      \"evidence\": \"peptide-HLA-E binding, NKG2A blocking, NK activation, and viral replication suppression in lung epithelial cells\",\n      \"pmids\": [\"35235832\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance during infection not established\", \"Structural basis of disrupted NKG2A binding not resolved here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Systematically defined which classical class I signal peptide variants are functionally processed for CD94/NKG2 engagement, showing surface HLA-E level and receptor recognition can be decoupled and that signal peptides compete for HLA-E.\",\n      \"evidence\": \"quantitative screen of 16 SP variants for HLA-E stabilization and CD94/NKG2A/C binding with competitive loading and NK assays\",\n      \"pmids\": [\"37264229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequences of SP competition not measured\", \"Did not extend to pathogen peptides\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the distinctive trafficking itinerary of HLA-E—ER retention from limited peptide and cytoplasmic-tail-driven surface internalization into late/recycling endosomes—setting it apart from classical class I.\",\n      \"evidence\": \"live imaging, FRAP, fractionation, cytoplasmic tail mutants, and trafficking inhibitor studies\",\n      \"pmids\": [\"37140910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endosomal recycling regulators not identified\", \"Functional consequence of intracellular pool unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a platelet-RGS18-AKT-GSK3β-CREB pathway driving HLA-E on circulating tumor cells to evade NK surveillance and promote metastasis, identifying a targetable upstream regulator.\",\n      \"evidence\": \"single-cell transcriptomics, NK killing assays, HLA-E knockdown, NKG2A blockade, and in vivo metastasis models\",\n      \"pmids\": [\"36706761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide presented by CTC HLA-E not defined\", \"Generalizability across tumor types untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established antigen-specific human NK cell memory mediated by NKG2C recognition of HLA-E peptide complexes, with single-cell cloning proving permanent epitope specificity.\",\n      \"evidence\": \"single-cell NK cloning, HLA-E tetramers, NKG2C blocking, and patient NK phenotyping for HIV and influenza\",\n      \"pmids\": [\"38064568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of memory imprinting not defined\", \"In vivo protective durability untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Used high-throughput yeast display to map a broad HLA-E peptidome capable of inhibitory and activating receptor signalling and trained predictive algorithms, expanding the known functional peptide space.\",\n      \"evidence\": \"yeast-display peptide library screen with HLA-E/CD94/NKG2x selection, NK functional assays, and machine-learning prediction\",\n      \"pmids\": [\"37558657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo presentation of predicted peptides unverified\", \"Structural rules underlying activating selection not derived\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed HLA-E-restricted CD8+ T cells recognize multiple SARS-CoV-2 peptides and suppress replication, with HLA-E surface levels preserved while classical class I is downregulated during infection—favoring HLA-E-restricted surveillance.\",\n      \"evidence\": \"T cell clone suppression assays and flow cytometry of HLA class I vs HLA-E in infected airway epithelial cells\",\n      \"pmids\": [\"37390223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism preserving HLA-E during infection not defined\", \"In vivo protection untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated EBV LMP-1 peptides presented by HLA-E act through NKG2A to inhibit NK and CD8 responses, while the high-expressing HLA-E*0103 genotype confers protection via BZLF1-specific HLA-E-restricted CD8 T cells.\",\n      \"evidence\": \"functional NK/CD8 and viral dissemination assays plus a 1404-patient cohort and peptide-HLA-E binding studies\",\n      \"pmids\": [\"36477802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking genotype to protective T cell priming not fully resolved\", \"Causality of clinical association limited\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the integrated peptide repertoire, allelic dosage, trafficking regulators, and competing signal peptides combine in vivo to set the balance between inhibitory and activating HLA-E signalling for therapeutic targeting.\",\n      \"evidence\": \"no single study in the corpus reconciles peptidome breadth with in vivo NK/T cell outcomes\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No in vivo map of which peptides dominate HLA-E presentation in healthy versus diseased tissue\", \"Endosomal recycling regulators of HLA-E unidentified\", \"Predictive rules distinguishing activating from inhibitory peptides not structurally complete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042605\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 7, 13, 29]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5, 6, 29]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [29, 18]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 9, 16, 30, 32]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 5, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 24, 26, 30, 31, 35]}\n    ],\n    \"complexes\": [\n      \"HLA-E/β2-microglobulin/peptide class I complex\"\n    ],\n    \"partners\": [\n      \"B2M\",\n      \"KLRD1\",\n      \"KLRC1\",\n      \"KLRC2\",\n      \"TAP\",\n      \"Nef\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}